

10.697.995  
10.20.04

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
WO 02/061090 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/13,  
15/70, 1/21, C07K 16/00, 19/00, A61K 47/48

C. [US/US]; 1313 Grove Avenue, Burlingame, CA 94010  
(US). KLIMOWSKI, Laura [CA/US]; 474 East 2nd Avenue, Salt Lake City, UT 84103 (US). REILLY, Dorothea E. [US/US]; 334 Mount Vernon, San Francisco, CA 94112-3634 (US). YANSURA, Daniel G. [US/US]; 330 Carmel Avenue, Pacifica, CA 94044 (US).

(21) International Application Number: PCT/US01/48691  
(22) International Filing Date:  
13 December 2001 (13.12.2001)

(74) Agent: CUI, Steven X.; c/o GENENTECH, INC., MS 49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(25) Filing Language: English  
(26) Publication Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(30) Priority Data:  
60/256,164 14 December 2000 (14.12.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),


(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, SOUTH SAN FRANCISCO, CA 94080 (US).

[Continued on next page]


(54) Title: PROKARYOTICALLY PRODUCED ANTIBODIES AND USES THEREOF



WO 02/061090 A2



pxTF2AP77



(57) Abstract: The present invention provides methods and compositions for improved expression and production of recombinant antibodies in prokaryotic expression systems. Particularly contemplated are prokaryotic expression and production of full-length glycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## PROKARYOTICALLY PRODUCED ANTIBODIES AND USES THEREOF

FIELD OF THE INVENTION

5 The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns recombinantly produced antibodies and uses thereof.

BACKGROUND OF THE INVENTION

Recent years have seen increasing promises of using antibodies as diagnostic and therapeutic agents for various disorders and diseases. Many research and clinical 10 applications require large quantities of functional antibodies, thus calling for large scale, economic production systems to be employed. Particularly useful is the recombinant production of antibodies using a variety of expression hosts, ranging from prokaryotes such as *E. coli* or *B. subtilis*, to yeast, plants, insect cells and mammalian cells. Kipriyanov and Little (1999) *Mol. Biotech.* 12:173-201.

15 Compared to other antibody production systems, bacteria, particularly *E. coli*, provides many unique advantages. The raw materials used (i.e. bacterial cells) are inexpensive and easy to grow, therefore reducing the cost of products. Shorter generation time and ease of scaling up make bacterial fermentation a more practical means for large-scale protein production. The genomic structure and biological activity of many bacterial 20 species, such as *E. coli*, have been well-studied and a wide range of expression vectors are available, making expression of a desirable antibody more convenient. Compared with eukaryotes, fewer steps are involved in the production process, including the manipulation of recombinant genes, stable transformation of multiple copies into the host, expression induction and characterization of the products. Pluckthun and Pack *Immunotech* 3:83-105 25 (1997). In addition, *E. coli* permits a unique access to random approaches. Because of the unparalleled efficiency for transformation by plasmids or transfection by phages, *E. coli* systems can be used for phage library construction of many types of antibody variants, which is particularly important in functional genomic studies.

Currently, bacterial systems are used to produce antibody fragments. Like any other 30 heterologous proteins, antibody fragments can be produced in *E. coli* either through refolding of inclusion bodies expressed in the cytoplasm, or through expression followed

by secretion to the bacterial periplasm. The choice between secretion and refolding is generally guided by several considerations. Secretion is generally the faster and more commonly used strategy.

Opperman et al., U.S. Pat. No. 6,008,023, describe an *E. coli* cytoplasmic expression system, wherein antibody fragments (e.g., Fabs) are fused with an enzyme for use in targeted tumor therapy. Zemel-Dreasen et al. *Gene* 27:315-322 (1984) report the secretion and processing of an antibody light chain in *E. coli*. Lo et al.'s PCT publication, WO 93/07896, reports the *E. coli* production of a tetrameric antibody lacking the CH2 region in its heavy chain. The genes encoding the light chain and the CH2-deleted heavy chain were constructed into the same expression vector, under the control of one single promoter. The authors acknowledged that the expression system was not optimized and the expression level was moderate. A similar polycistronic system, wherein two expression units (i.e., cistrons) were under the control of one promoter, was used by Carter et al. in U.S. Pat. No. 5,648,237, for producing antibody fragments in *E. coli*.

In contrast to the widespread uses of bacterial systems for expressing antibody fragments, there have been few attempts to express and recover at high yield functional intact antibodies in *E. coli*. Because of the complex feature and large size of an intact antibody, it is often difficult to achieve proper folding and assembly of the expressed light and heavy chain polypeptides, resulting in poor yield of reconstituted tetrameric antibody. Furthermore, since antibodies made in prokaryotes are not glycosylated, thus lacking the effector functions, the art has suggested that *E. coli* would not be a useful system for making intact antibodies. Pluckthun and Pack (1997) *Immunotech* 3:83-105; Kipriyanov and Little *Mol. Biotech.* 12:173-201 (1999); Pluckthun et al. (1996) in **ANTIBODY ENGINEERING: A PRACTICAL APPROACH**, pp 203-252 (Oxford Press); Pluckthun (1994) in **HANDBOOK OF EXP. PHARMCOL** vol 3: The Pharmacol. of Monoclonal Antibodies, pp269-315 (ed. M. Rosenberg and G.P. Moore; Springer-Verlag, Berlin).

Recent developments in research and clinical studies suggest that in many instances, intact antibodies are preferred over antibody fragments. An intact antibody containing the Fc region tends to be more resistant against degradation and clearance *in vivo*, thereby having longer biological half life in circulation. This feature is particularly desirable where the antibody is used as a therapeutic agent for diseases requiring sustained therapies.

Furthermore, in many instances, intact antibodies deficient in effector functions are more desirable for therapeutic uses. Friend et al., *Transplantation* 68: 1632-1637 (1999) describe toxic effects, such as severe cytokine release syndromes, of glycosylated CD3 monoclonal antibodies when used in humans for the treatment of acute rejection episodes 5 of organ allografts. The CD3 antibodies cause T-cell activation and cytokine release by cross-linking the T cell receptor complex as a result of FcR binding. U.S. Pat. No. 5,585,097 describe making aglycosylated CD3 antibodies by mutating certain glycosylation site residues of native CD3 antibodies. Armour et al., *Eur. J. Immunol.* 29:2613-2624 10 (1999) describe the use of non-destructive antibodies (i.e., lacking the effector functions) specific for HPA-1a-positive platelets in therapeutic applications where depletion of cells bearing the target antigen (i.e., the platelet cells) is undesirable. Thompson, et al., *J. Immunol. Meth.* 227:17-29 (1999) show that effector functions of a fully human antibody against TGF $\beta$ 2 are not necessary for use in therapy of fibrotic diseases mediated by TGF $\beta$ 2. Reddy, et al., *J. Immunol.* 164:1925-1933 (2000) describe liability of strong 15 antibody-Fc $\gamma$  receptor binding in treating autoimmune diseases; Isaacs, et al., *Clin. Exp. Immunol.* 106:427-433(1996) suggest that if a pure blocking effect is required *in vivo*, an aglycosylated monoclonal antibody variant or a mutant engineered to prevent Fc receptor binding may be better choices.

Currently, attempts to eliminate or reduce effector functions of an antibody focus on 20 either using IgG4 isotype, which is thought to be unable to deplete target cells, or making Fc variants, wherein residues in the Fc region critical for effector function(s) are mutated. See, for example, U.S. Pat. No. 5,585,097. However, both of these approaches have limitations. For example, the IgG4 isotype has been shown to retain some level of effector functions, as described by Isaacs, et al. (1996) *supra*, and Thompson, et al. (1999), *supra*. 25 Reddy et al. (2000), *supra*, also report that further alterations of an IgG4 mAb against CD4 were required to eliminate Fc effector functions. Fc mutants may elicit undesirable immune response because of the residue changes in the primary sequence.

#### SUMMARY OF THE INVENTION

The present invention addresses the need for producing intact antibodies in 30 prokaryotic organisms. In one embodiment, the invention provides a process for producing an immunoglobulin in a prokaryotic host cell, comprising using a uniquely designed separate cistron expression vector. The separate cistron expression vector of the invention

comprises a polynucleotide expression cassette, which comprises a first promoter-cistron pair for expression of an immunoglobulin light chain and a second promoter-cistron pair for expression of an immunoglobulin heavy chain, whereby expression of the light chain and heavy chain are independently regulated by separate promoters. Each cistron within  
5 the expression cassette polynucleotide comprises a translation initiation region (TIR) operably linked to the nucleic acid sequence coding for the light chain or heavy chain of the full length antibody. In some embodiments, the TIR sequences within the expression vector of the invention are manipulated so to provide different translational strength combinations for light and heavy chains. Many prokaryotic organisms are suitable as hosts  
10 for the expression vector of the invention. Preferably, the host is a gram-negative bacteria.

More preferably, the host is *E. coli*. In one embodiment, the host cell is a genetically altered *E. coli* strain suitable for large quantity production of heterologous proteins. A number of promoters can be used for the expression vector of the invention. A preferred promoter is the *E. coli* PhoA promoter.

15 The invention also provides a full length aglycosylated antibody produced in a prokaryotic host using the novel separate cistron expression vector. The invention encompasses various antibody modifications or variants, including but not limited to humanized antibodies, affinity matured antibodies, antibodies with variant Fc regions, multispecific antibodies, and antibody derivatives. Immunoconjugate compositions  
20 comprising the full length antibody conjugated to a cytotoxic agent are also contemplated.

Also contemplated are various diagnostic and therapeutic uses of the full length antibodies described herein. In one therapeutic application, the full length antibody is used in combination with another therapeutic agent in a patient.

#### BRIEF DESCRIPTION OF DRAWINGS

25 **Figure 1** is a schematic representation of the construction of a full length antibody expression vector, pxTFPV, based on an existing Fab expression vector, pAK19.

**Figure 2** shows *E. coli* expression of full length antibodies using two polycistronic full length antibody expression vectors. Whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. Lane 1 is negative control; lane 2 is pxTFPV (anti-TF antibody); and lane 3 is pY0317.Fab-CH3 (anti-VEGF antibody). The arrow indicates  
30 bands corresponding to full length antibodies.

**Figure 3** depicts polycistronic constructs with various TIR translational strength combinations for light and heavy chains.

**Figures 4A and 4B** show *E. coli* expression of full length anti-TF IgG1 using polycistronic vectors with various TIR combinations for light (L) and heavy (H) chains.

5 Whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. (4A) reduced samples. (4B) non-reduced samples. Listed above each lane is the relative TIR translational strength for light ("L") and heavy ("H") chains. "neg.": induced cells harboring only the background vector, pBR322.

10 **Figure 5** is a schematic representation of the constructions for the individual expression of light and heavy chains under different TIR translational strengths.

**Figures 6A and 6B** are Coomassie stained gel results of reduced whole cell lysate samples for different plasmids, showing the effect of TIR relative strength on the secretion yields of light chain (6A) and heavy chain (6B).

15 **Figure 7** schematically illustrates the construction of a separate cistron expression vector for full length antibody (pxTF2AP77) by combining light and heavy chain vectors with determined TIR strengths.

**Figure 8** shows Coomassie staining of reduced whole cell lysate transformed with the separate cistron vector pxTF2AP77.

20 **Figure 9** illustrates separate cistron constructs with various TIR strength combinations for light and heavy chains.

**Figures 10A and 10B** show *E. coli* expression of full length anti-TF IgG1 using separate cistron constructs with various TIR strength combinations for light (L) and heavy (H) chains. Whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. (4A) reduced samples. (4B) non-reduced samples. Listed above each lane is the relative TIR translational strength for light ("L") and heavy ("H") chains. "neg.": induced cells harboring only the background vector, pBR322.

25 **Figure 11** is a comparison of full length antibody expressions using the polycistronic vs. the separate cistron systems. Non-reduced whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. Various TIR strength combinations for light (L) and heavy (H) chains are indicated.

**Figure 12** is a Coomassie-stained gel comparison of the pAK19-derived polycistronic vector vs. the separate cistron vector for anti-TF antibody. Lane 1 is a negative control; lane 2 is pxTFPV (pAK19-derived polycistronic); and lane 3 is paTF50 (separate cistron). The arrow indicates the position for full length antibodies.

5       **Figure 13** is a comparison of the full length anti-TF antibody expression using a pAK19-derived polycistronic vector vs. a separate cistron vector. Non-reduced whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. Lane 1 is a negative control; lane 2 is pxTFPV (pAK19-derived polycistronic); and lane 3 is paTF50 (separate cistron). The arrow indicates the band corresponding to full length antibody.

10      **Figure 14** is a comparison of the full length anti-VEGF antibody expression using a pAK19-derived polycistronic vector vs. a separate cistron vector. Non-reduced whole cell lysates were analyzed by SDS-PAGE immunoblot following induction. Lane 1 is a negative control; lane 2 is pY0317.Fab-CH3 (pAK19-derived polycistronic); and lane 3 is pxVG2AP11 (separate cistron). The arrow indicates the band representing full length anti-  
15     VEGF antibody.

**Figure 15** depicts the antigen (TF) binding of the full length anti-TF antibody made by the separate cistron vector paTF50 in *E. coli* (IgG1). Two CHO-made anti-TF antibodies (IgG2 and IgG4) were used as controls.

20      **Figure 16** depicts the C1q binding of the full length anti-TF antibody IgG1 made by paTF50 in *E. coli*. Another antibody, I-1095-1-Rituximab, was used for comparison.

**Figure 17** depicts the Fc $\gamma$ R1 alpha binding of the full length anti-TF antibody made by paTF50 in *E. coli*. Two anti-IgE antibodies made in CHO cells were used as controls.

25      **Figure 18** depicts the FcRn binding of the full length anti-TF antibody IgG1 made by paTF50 in *E. coli* (32604-74 E coli IgG1) in comparison with five other antibodies as controls.

**Figure 19** depicts the plasma anti-TF antibody (ATF-D3H44) concentration ( $\mu$ g/ml) changes over time in chimpanzees given a single IV bolus dose of either the full length IgG1 made by paTF50 in *E. coli* (IgG1 *E. coli*), the IgG2 made in CHO (IgG2 CHO) or the IgG4b made in CHO (IgG4b CHO).

**Figures 20a-20c** show the expression cassette sequences of the separate cistron vector **paTF50**.

**Figures 21a-21c** show the expression cassette sequences of the separate cistron vector **pxVG2AP11**.

5       **Figure 22** shows expression of various full length antibodies using the separate cistron system. Whole cell lysates were analyzed by SDS-PAGE immunoblot following induction.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### **I. Definitions**

10       The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a phage vector. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of 15       directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "recombinant vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector.

20       The term "cistron," as used herein, is intended to refer to a genetic element broadly equivalent to a translational unit comprising the nucleotide sequence coding for a polypeptide chain and adjacent control regions. "Adjacent control regions" include, for example, a translational initiation region (TIR; as defined herein below) and a termination region.

25       A "polycistronic" expression vector refers to a single vector that contains and expresses multiple cistrons under the regulatory control of one single promoter. A

common example of polycistronic vector is a "dicistronic" vector that contains and expresses two different polypeptides under the control of one promoter. Upon expression of a dicistronic or polycistronic vector, multiple genes are first transcribed as a single transcriptional unit, and then translated separately.

5        A "separate cistron" expression vector according to the present invention refers to a single vector comprising at least two separate promoter-cistron pairs, wherein each cistron is under the control of its own promoter. Upon expression of a separate cistron expression vector, both transcription and translation processes of different genes are separate and independent.

10       The "translation initiation region" or TIR, as used herein refers to a nucleic acid region providing the efficiency of translational initiation of a gene of interest. In general, a TIR within a particular cistron encompasses the ribosome binding site (RBS) and sequences 5' and 3' to RBS. The RBS is defined to contain, minimally, the Shine-Dalgarno region and the start codon (AUG). Accordingly, a TIR also includes at least a portion of the nucleic acid sequence to be translated. Preferably, a TIR of the invention includes a secretion signal sequence encoding a signal peptide that precedes the sequence encoding for the light or heavy chain within a cistron. A TIR variant contains sequence variants (particularly substitutions) within the TIR region that alter the property of the TIR, such as its translational strength as defined herein below. Preferably, a TIR variant of the invention contains sequence substitutions within the first 2 to about 14, preferably about 4 to 12, more preferably about 6 codons of the secretion signal sequence that precedes the sequence encoding for the light or heavy chain within a cistron.

15       The term "translational strength" as used herein refers to a measurement of a secreted polypeptide in a control system wherein one or more variants of a TIR is used to direct secretion of a polypeptide and the results compared to the wild-type TIR or some other control under the same culture and assay conditions. Without being limited to any one theory, "translational strength" as used herein can include, for example, a measure of mRNA stability, efficiency of ribosome binding to the ribosome binding site, and mode of translocation across a membrane.

20       "Secretion signal sequence" or "signal sequence" refers to a nucleic acid sequence encoding for a short signal peptide that can be used to direct a newly synthesized protein of interest through a cellular membrane, usually the inner membrane or both inner and outer

membranes of prokaryotes. As such, the protein of interest such as the immunoglobulin light or heavy chain polypeptide is secreted into the periplasm of the prokaryotic host cells or into the culture medium. The signal peptide encoded by the secretion signal sequence may be endogenous to the host cells, or they may be exogenous, including signal peptides native to the polypeptide to be expressed. Secretion signal sequences are typically present at the amino terminus of a polypeptide to be expressed, and are typically removed enzymatically between biosynthesis and secretion of the polypeptide from the cytoplasm. Thus, the signal peptide is usually not present in a mature protein product.

The term "host cell" (or "recombinant host cell"), as used herein, is intended to refer to a cell that has been genetically altered, or is capable of being genetically altered by introduction of an exogenous polynucleotide, such as a recombinant plasmid or vector. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

The terms "antibody" and "immunoglobulin" are used interchangeably in the broadest sense and includes monoclonal antibodies (full length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, and multispecific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity). A naturally occurring antibody comprises four polypeptide chains, two identical heavy (H) chains and two identical light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region ( $V_H$ ) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region ( $V_L$ ) and a light chain constant region. The light chain constant region is comprised of one domain,  $C_L$ . The  $V_H$  and  $V_L$  regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each  $V_H$  and  $V_L$  is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The light chains of antibodies from any vertebrate species can be assigned to one of

two clearly distinct types, called kappa ( $\kappa$ ) and lambda ( $\lambda$ ), based on the amino acid sequences of their constant domains.

Depending on the amino acid sequences of the constant domains of their heavy chains, antibodies (immunoglobulins) can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgA-1, IgA-2, and etc. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called  $\alpha$ ,  $\delta$ ,  $\epsilon$ ,  $\gamma$ , and  $\mu$ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known and described generally in, for example, Abbas et al. *Cellular and Mol. Immunology*, 4th ed. (2000). An antibody may be part of a larger fusion molecule, formed by covalent or non-covalent association of the antibody with one or more other proteins or peptides.

The terms "full length antibody," "intact antibody" and "whole antibody" are used herein interchangeably, to refer to an antibody in its substantially intact form, not antibody fragments as defined below. The terms particularly refer to an antibody with heavy chains that contains the Fc region. A full length antibody can be a native sequence antibody or an antibody variant. A full length antibody can be human, humanized and/or affinity matured.

"Antibody fragments" comprise only a portion of an intact antibody, generally including an antigen binding site of the intact antibody and thus retaining the ability to bind antigen. Examples of antibody fragments encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CH1 domains; (ii) the Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CH1 domain; (iii) the Fd fragment having VH and CH1 domains; (iv) the Fd' fragment having VH and CH1 domains and one or more cysteine residues at the C-terminus of the CH1 domain; (v) the Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) the dAb fragment which consists of a VH domain; (vii) isolated CDR regions; (viii) F(ab')<sub>2</sub> fragments, a bivalent fragment including two Fab' fragments linked by a disulfide bridge at the hinge region; (ix) single chain antibody molecules (e.g. single chain Fv; scFv); (x) "diabodies" with two antigen binding sites, comprising a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain; (xi) "linear antibodies" comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair

of antigen binding regions.

A "biologically active" or "functional" immunoglobulin is one capable of exerting one or more of its natural activities in structural, regulatory, biochemical or biophysical events. For example, a biologically active antibody may have the ability to specifically bind an antigen and the binding may in turn elicit or alter a cellular or molecular event such as signaling transduction or enzymatic activity. A biologically active antibody may also block ligand activation of a receptor or act as an agonist antibody. The capability of a full length antibody to exert one or more of its natural activities depends on several factors, including proper folding and assembly of the polypeptide chains. As used herein, the biologically active immunoglobulins generated by the disclosed methods are typically heterotetramers having two identical L chains and two identical H chains that are linked by multiple disulfide bonds and properly folded.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984)).

"Humanized" forms of non-human (*e.g.*, murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a

hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise 5 residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human 10 immunoglobulin sequence. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature* 321:522-525 (1986); Riechmann *et al.*, *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992). See also the following review articles and references cited therein: Vaswani 15 and Hamilton, *Ann. Allergy, Asthma & Immunol.* 1:105-115 (1998); Harris, *Biochem. Soc. Transactions* 23:1035-1038 (1995); Hurle and Gross, *Curr. Op. Biotech.* 5:428-433 (1994).

A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a 20 human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.

An "affinity matured" antibody is one with one or more alterations in one or more CDRs thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s). Preferred 25 affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks *et al.* *Bio/Technology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by: Barbas *et al.* *Proc Nat. Acad. Sci, USA* 91:3809-3813 (1994); Schier *et al.* *Gene* 30 169:147-155 (1995); Yelton *et al.* *J. Immunol.* 155:1994-2004 (1995); Jackson *et al.*, *J. Immunol.* 154(7):3310-9 (1995); and Hawkins *et al.* *J. Mol. Biol.* 226:889-896 (1992).

The term "Fc region" is used to define the C-terminal region of an immunoglobulin

heavy chain which may be generated by papain digestion of an intact antibody. The Fc region may be a native sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at about position Cys226, 5 or from about position Pro230, to the carboxyl-terminus of the Fc region. The Fc region of an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain. By "Fc region chain" herein is meant one of the two polypeptide chains of an Fc region.

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells, express Fc $\gamma$ RIII only, whereas monocytes express Fc $\gamma$ RI, Fc $\gamma$ RII and Fc $\gamma$ RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of 10 Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-92 (1991). To assess ADCC activity of a molecule of interest, an *in vitro* ADCC assay, such as that described in US Patent No. 15 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed *in vivo*, e.g., in 15 a animal model such as that disclosed in Clynes *et al.* *PNAS (USA)* 95:652-656 (1998). 20

The terms "Fc receptor" and "FcR" are used to describe a receptor that binds to the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the Fc $\gamma$ RI, Fc $\gamma$ RII, and Fc $\gamma$ RIII subclasses, including allelic variants and 25 alternatively spliced forms of these receptors. Fc $\gamma$ RII receptors include Fc $\gamma$ RIIA (an "activating receptor") and Fc $\gamma$ RIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor Fc $\gamma$ RIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor Fc $\gamma$ RIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain (reviewed in Daëron, *Annu. Rev. Immunol.* 15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, *Annu. Rev. Immunol.* 9:457-92 (1991); Capel *et al.*, *Immunomethods* 4:25-34 (1994); and de Haas *et* 30

*al., J. Lab. Clin. Med.* 126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term "FcR" herein. The term also includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus (Guyer *et al.*, *J. Immunol.* 117:587 (1976); and Kim *et al.*, *J. Immunol.* 24:249 (1994)).

5 "Complement dependent cytotoxicity" and "CDC" refer to the lysing of a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (e.g. an antibody) complexed with a cognate antigen. To assess complement activation, a CDC assay, *e.g.* as described in Gazzano-Santoro *et al.*, *J. Immunol. Methods* 202:163 (1996),  
10 may be performed.

15 "Affinity binding" refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or FcRn receptor). The affinity of a molecule X for its partner Y is represented by the dissociation constant (Kd), which is the concentration of Y that is required to occupy the combining sites of half the X molecules present in a solution. Low-affinity antibodies bind antigen (or FcRn receptor) weakly and tend to dissociate readily, whereas high-affinity antibodies bind antigen (or FcRn receptor) more tightly and remain bound longer.

20 The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The term is intended to include radioactive isotopes (e.g. At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup>, P<sup>32</sup> and radioactive isotopes of Lu), chemotherapeutic agents, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof.

25 A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylololomelamine;  
30 acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1

and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin,

5 phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyne antibiotics (*e.g.* calicheamicin, especially calicheamicin  $\gamma_1^I$  and calicheamicin  $\theta_1^I$ , see, *e.g.*, Agnew *Chem Int'l. Ed. Engl.* 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein

10 enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabacin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin,

15 marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodóubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprime, thioguanine; pyrimidine

20 analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil;

25 bisantrene; edatraxate; defofamine; demecolcine; diaziquone; el fornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; rhizoxin; sizofiran; spirogermanium;

30 tenuazonic acid; triaziquone; 2, 2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, *e.g.* paclitaxel (TAXOL®, Bristol-Myers Squibb

Oncology, Princeton, NJ) and doxetaxel (TAXOTERE®, Rhône-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; 5 novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, 10 raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

A "blocking" antibody or an "antagonist" antibody is one which inhibits or reduces 15 biological activity of the antigen it binds. Such blocking can occur by any means, *e.g.* by interfering with: ligand binding to the receptor, receptor complex formation, tyrosine kinase activity of a tyrosine kinase receptor in a receptor complex and/or phosphorylation of tyrosine kinase residue(s) in or by the receptor. For example, a VEGF antagonist antibody binds VEGF and inhibits the ability of VEGF to induce vascular endothelial cell 20 proliferation. Preferred blocking antibodies or antagonist antibodies completely inhibit the biological activity of the antigen.

An "agonist antibody" is an antibody which binds and activates antigen such as a receptor. Generally, the receptor activation capability of the agonist antibody will be at least qualitatively similar (and may be essentially quantitatively similar) to a native agonist 25 ligand of the receptor.

An antibody of the invention "which binds antigen essentially as effectively as" a corresponding antibody made in a mammalian cell system, is one capable of binding that antigen with affinity or avidity that is within about 10 fold, preferably about 5 fold, and more preferably about 2 fold, of the binding affinity of an antibody that is expressed by a 30 mammalian cell, such as a Chinese Hamster Ovary (CHO) cell.

A "disorder" is any condition that would benefit from treatment with the antibody. This includes chronic and acute disorders or diseases including those pathological

conditions which predispose the mammal to the disorder in question. Non-limiting examples of disorders to be treated herein include malignant and benign tumors; non-leukemias and lymphoid malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, 5 angiogenic and immunologic disorders.

An "autoimmune disease" herein is a non-malignant disease or disorder arising from and directed against an individual's own tissues. The autoimmune diseases herein specifically exclude malignant or cancerous diseases or conditions, especially excluding B cell lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia 10 (CLL), Hairy cell leukemia and chronic myeloblastic leukemia. Examples of autoimmune diseases or disorders include, but are not limited to, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (*e.g.* atopic dermatitis); systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including 15 adult respiratory distress syndrome; ARDS); dermatitis; meningitis; encephalitis; uveitis; colitis; glomerulonephritis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (*e.g.* Type I diabetes mellitus or insulin dependent 20 diabetes mellitus); multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and 25 vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia (including, but not limited to cryoglobulinemia or Coombs positive 30 anemia); myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia etc.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.

More particular examples of such cancers include squamous cell cancer, small-cell lung

5 cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval

10 cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.

As used herein, "treatment" refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, alleviation of symptoms,

15 diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.

An "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A "therapeutically effective amount" of the antibody may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and

20 for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

25

## II. Mode(s) for Carrying out the Invention

The present invention concerns the recombinant production of immunoglobulins in

30 a prokaryotic system. The invention is based on a uniquely designed expression vector, in which the expressions of an immunoglobulin light chain and an immunoglobulin heavy chain are independently modulated (i.e., a separate cistron system). As illustrated in some

of the examples provided herein, significant problems are associated with existing prokaryotic systems for antibody production, in which the transcription of light and heavy chain genes are under the control of one promoter (i.e., the polycistronic systems). Such systems tend to create unbalanced expression levels of the two immunoglobulin chains.

5 When two genes are expressed from a single transcriptional unit, the first gene is typically expressed at a higher level than the second gene. This effect results from the translational dependency of the second gene on such additional factors as the efficiency of ribosomal coupling between the two genes. Accordingly, the polycistronic system produces an excess of light chain over heavy chain. This particular issue could in theory be improved by

10 experimentally increasing the translational coupling. However, even if efficient translational coupling could be obtained between the chains, the polycistronic system creates an additional hurdle in complicating the determination of preferred light to heavy chain expression ratios. Since both chains are tied together on the same message, manipulating the translation of the first gene (light chain) affects the translation of the

15 second gene (heavy chain). Considerable time and effort would be required to overcome such a complicated arrangement to achieve desirable ratios of light to heavy chain expression.

It has now been surprisingly discovered that the problem associated with the polycistronic system can be solved by using a separate cistron system, wherein each of the

20 cistrons for light chain and heavy chain genes is paired with, and under the control of, a separate promoter, thus allowing separation and independence of both transcription and translation of the two genes. While it is generally desirable to obtain high expression levels for individual chains of an antibody, more important for maximizing production of full length, correctly folded, biologically active antibodies is obtaining desirable ratios of light

25 to heavy chain expression.

While the separate cistron expression system of the present invention is mainly illustrated for the production of immunoglobulins, it should be understood that the approach described herein is applicable in any system in which multimeric proteins are to be produced and the final protein complex requires proper assembly of individual

30 units/chains in order to be functional. The approach is especially useful for the production of protein complexes containing disulfide bonds including for example, but not limited to, T-cell receptors, class I and class II MHC molecules, integrins, CD8, CD28 and Factor VIII

molecules, and related derivatives, variants and fusion proteins.

### Antigen Specificity

The present invention is applicable to antibodies of any appropriate antigen binding specificity. Preferably, the antibodies of the invention are specific to antigens that are 5 biologically important polypeptides. More preferably, the antibodies of the invention are useful for therapy or diagnosis of diseases or disorders in a mammal. The full length aglycosylated antibodies made according to the present invention are particularly useful as therapeutic antibodies such as blocking antibodies, agonist antibodies or antibody conjugates. Non-limiting examples of therapeutic antibodies include anti-VEGF, anti-IgE, 10 anti-CD11, anti-CD18, anti-CD40, anti-tissue factor (TF), anti-HER2, and anti-TrkC antibodies. Antibodies directed against non-polypeptide antigens (such as tumor-associated glycolipid antigens) are also contemplated.

Where the antigen is a polypeptide, it may be a transmembrane molecule (*e.g.* receptor) or a ligand such as a growth factor. Exemplary antigens include molecules such 15 as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIIC, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting 20 factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha); a serum albumin such as human 25 serum albumin; Muellerian-inhibiting substance; relaxin A-chain; relaxin B-chain; prorelaxin; mouse gonadotropin-associated peptide; a microbial protein, such as beta-lactamase; DNase; IgE; a cytotoxic T-lymphocyte associated antigen (CTLA), such as CTLA-4; inhibin; activin; vascular endothelial growth factor (VEGF); receptors for hormones or growth factors; protein A or D; rheumatoid factors; a neurotrophic factor such 30 as bone-derived neurotrophic factor (BDNF), neurotrophin-3, -4, -5, or -6 (NT-3, NT-4, NT-5, or NT-6), or a nerve growth factor such as NGF- $\beta$ ; platelet-derived growth factor (PDGF); fibroblast growth factor such as aFGF and bFGF; epidermal growth factor (EGF);

transforming growth factor (TGF) such as TGF-alpha and TGF-beta, including TGF- $\beta$ 1, TGF- $\beta$ 2, TGF- $\beta$ 3, TGF- $\beta$ 4, or TGF- $\beta$ 5; insulin-like growth factor-I and -II (IGF-I and IGF-II); des(1-3)-IGF-I (brain IGF-I), insulin-like growth factor binding proteins; CD proteins such as CD3, CD4, CD8, CD19, CD20 and CD40; erythropoietin; osteoinductive factors; 5 immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon-alpha, -beta, and -gamma; colony stimulating factors (CSFs), *e.g.*, M-CSF, GM-CSF, and G-CSF; interleukins (ILs), *e.g.*, IL-1 to IL-10; superoxide dismutase; T-cell receptors; surface membrane proteins; decay accelerating factor; viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory 10 proteins; integrins such as CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 or HER4 receptor; and fragments of any of the above-listed polypeptides.

Preferred antigens for antibodies encompassed by the present invention include CD proteins such as CD3, CD4, CD8, CD19, CD20, CD34, and CD46; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-1, Mac1, p150.95, VLA-4, ICAM-1, VCAM,  $\alpha$ 4/ $\beta$ 7 integrin, and  $\alpha$ v/ $\beta$ 3 integrin including either  $\alpha$  or  $\beta$  subunits thereof (*e.g.* anti-CD11a, anti-CD18 or anti-CD11b antibodies); growth factors such as VEGF; tissue factor (TF); TGF- $\beta$  alpha interferon ( $\alpha$ -IFN); an interleukin, such as IL-8; IgE; blood group antigens Apo2, death 15 receptor; flk2/flt3 receptor; obesity (OB) receptor; *mpl* receptor; CTLA-4; protein C etc. 20 The most preferred targets herein are VEGF, TF, CD19, CD20, CD40, TGF- $\beta$ , CD11a, CD18, Apo2 and C24.

Soluble antigens or fragments thereof, optionally conjugated to other molecules, can be used as immunogens for generating antibodies. For transmembrane molecules, such 25 as receptors, fragments of these molecules (*e.g.* the extracellular domain of a receptor) can be used as the immunogen. Alternatively, cells expressing the transmembrane molecule can be used as the immunogen. Such cells can be derived from a natural source (*e.g.* cancer cell lines) or may be cells which have been transformed by recombinant techniques to express the transmembrane molecule. Other antigens and forms thereof useful for 30 preparing antibodies will be apparent to those in the art.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific to different epitopes

of a single molecule or may be specific to epitopes on different molecules. Methods for designing and making multispecific antibodies are known in the art. See, e.g., Millstein et al. (1983) *Nature* 305:537-539; Kostelny et al. (1992) *J. Immunol.* 148:1547-1553; WO 93/17715.

## 5 Vector Construction

Polynucleotide sequences encoding the immunoglobulin light and heavy chains of the invention can be obtained using standard recombinant techniques. Desired polynucleotide sequences may be isolated and sequenced from antibody producing cells such as hybridoma cells. Alternatively, polynucleotides can be synthesized using 10 nucleotide synthesizer or PCR techniques. Once obtained, sequences encoding the light and heavy chains are inserted into a recombinant vector capable of replicating and expressing heterologous polynucleotides in prokaryotic hosts. Many vectors that are available and known in the art can be used for the purpose of the present invention.

Selection of an appropriate vector will depend mainly on the size of the nucleic acids to be 15 inserted into the vector and the particular host cell to be transformed with the vector. Each vector contains various components, depending on its function (amplification or expression of heterologous polynucleotide, or both) and its compatibility with the particular host cell in which it resides. The vector components generally include, but are not limited to: an origin of replication, a selection marker gene, a promoter, a ribosome binding site (RBS), a 20 signal sequence, the heterologous nucleic acid insert and a transcription termination sequence.

In general, plasmid vectors containing replicon and control sequences which are derived from species compatible with the host cell are used in connection with these hosts. The vector ordinarily carries a replication site, as well as marking sequences which are 25 capable of providing phenotypic selection in transformed cells. For example, *E. coli* is typically transformed using pBR322, a plasmid derived from an *E. coli* species. pBR322 contains genes encoding ampicillin (Amp) and tetracycline (Tet) resistance and thus provides easy means for identifying transformed cells. pBR322, its derivatives, or other microbial plasmids or bacteriophage may also contain, or be modified to contain, 30 promoters which can be used by the microbial organism for expression of endogenous proteins. Examples of pBR322 derivatives used for expression of particular antibodies are

described in detail in Carter et al., U.S. Patent No. 5,648,237, and the "Examples" section herein below.

In addition, phage vectors containing replicon and control sequences that are compatible with the host microorganism can be used as transforming vectors in connection 5 with these hosts. For example, bacteriophage such as  $\lambda$ GEM.TM.-11 may be utilized in making a recombinant vector which can be used to transform susceptible host cells such as *E. coli* LE392.

The expression vector of the invention comprises at least two promoter-cistron pairs, one for the immunoglobulin light chain and the other for the immunoglobulin heavy 10 chain. Promoter is an untranslated regulatory sequence located upstream (5') to a cistron that modulate its expression. Prokaryotic promoters typically fall into two classes, inducible and constitutive. Inducible promoter is a promoter that initiates increased levels of transcription of the cistron under its control in response to changes in the culture condition, e.g. the presence or absence of a nutrient or a change in temperature.

15 Although both constitutive and inducible promoters can be used in the present invention, inducible promoters under high regulation are preferred in the expression vectors disclosed herein. A large number of promoters recognized by a variety of potential host cells are well known. The selected promoter can be operably linked to cistron DNA encoding the light or heavy chain by removing the promoter from the source DNA via 20 restriction enzyme digestion and inserting the isolated promoter sequence into the vector of the invention. Both the native promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of the target genes. However, heterologous promoters are preferred, as they generally permit greater transcription and higher yields of expressed target gene as compared to the native target polypeptide 25 promoter.

Promoters suitable for use with prokaryotic hosts include the PhoA promoter, the  $\beta$ -galactamase and lactose promoter systems, a tryptophan (trp) promoter system and hybrid promoters such as the *tac* or the *trc* promoter. However, other promoters that are functional in bacteria (such as other known bacterial or phage promoters) are suitable as 30 well. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to cistrons encoding the target light and heavy chains (Siebenlist et

al. (1980) Cell 20: 269) using linkers or adaptors to supply any required restriction sites. More preferred promoter for use in this invention is the PhoA promoter.

In one aspect of the present invention, each cistron within the recombinant vector comprises a secretion signal sequence component that directs translocation of the expressed 5 polypeptides across a membrane. In general, the signal sequence may be a component of the vector, or it may be a part of the target polypeptide DNA that is inserted into the vector. The signal sequence selected for the purpose of this invention should be one that is recognized and processed (i.e. cleaved by a signal peptidase) by the host cell. For prokaryotic host cells that do not recognize and process the signal sequences native to the 10 heterologous polypeptides, the signal sequence is substituted by a prokaryotic signal sequence selected, for example, from the group consisting of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II (STII) leaders, LamB, PhoE, PelB, OmpA and MBP. In a preferred embodiment of the invention, the signal sequences used in both cistrons of the expression system are STII signal sequences or variants thereof.

15 In another aspect, the production of the immunoglobulins according to the invention can occur in the cytoplasm of the host cell, and therefore does not require the presence of secretion signal sequences within each cistron. In that regard, immunoglobulin light and heavy chains are expressed, folded and assembled to form functional immunoglobulins within the cytoplasm. Certain host strains (e.g., the *E. coli* *trxB*<sup>-</sup> strains) provide cytoplasm 20 conditions that are favorable for disulfide bond formation, thereby permitting proper folding and assembly of expressed protein subunits. Proba and Pluckthun *Gene*, 159:203 (1995).

25 The present invention provides an expression system in which the quantitative ratio of expressed light and heavy chains can be modulated in order to maximize the yield of secreted and properly assembled full length antibodies. Such modulation is accomplished by simultaneously modulating translational strengths for light and heavy chains.

One technique for modulating translational strength is disclosed in Simmons et al. U.S. Pat. No. 5, 840,523. It utilizes variants of the translational initiation region (TIR) within a cistron. For a given TIR, a series of amino acid or nucleic acid sequence variants 30 can be created with a range of translational strengths, thereby providing a convenient means by which to adjust this factor for the desired expression level of the specific chain. TIR variants can be generated by conventional mutagenesis techniques that result in codon

changes which can alter the amino acid sequence, although silent changes in the nucleotide sequence are preferred. Alterations in the TIR can include, for example, alterations in the number or spacing of Shine-Dalgarno sequences, along with alterations in the signal sequence. One preferred method for generating mutant signal sequences is the generation 5 of a "codon bank" at the beginning of a coding sequence that does not change the amino acid sequence of the signal sequence (i.e., the changes are silent). This can be accomplished by changing the third nucleotide position of each codon; additionally, some amino acids, such as leucine, serine, and arginine, have multiple first and second positions that can add complexity in making the bank. This method of mutagenesis is described in 10 detail in Yansura et al. (1992) *METHODS: A Companion to Methods in Enzymol.* 4:151-158.

Preferably, a set of vectors is generated with a range of TIR strengths for each cistron therein. This limited set provides a comparison of expression levels of each chain as well as the yield of full length products under various TIR strength combinations. TIR 15 strengths can be determined by quantifying the expression level of a reporter gene as described in detail in Simmons et al. U.S. Pat. No. 5, 840,523. For the purpose of this invention, the translational strength combination for a particular pair of TIRs within a vector is represented by (N-light, M-heavy), wherein N is the relative TIR strength of light chain and M is the relative TIR strength of heavy chain. For example, (3-light, 7-heavy) 20 means the vector provides a relative TIR strength of about 3 for light chain expression and a relative TIR strength of about 7 for heavy chain expression. Based on the translational strength comparison, the desired individual TIRs are selected to be combined in the expression vector constructs of the invention.

Prokaryotic host cells suitable for expressing full length antibodies of the invention 25 include Archaeabacteria and Eubacteria, such as Gram-negative or Gram-positive organisms. Examples of useful bacteria include Escherichia (e.g., *E. coli*), Bacilli (e.g., *B. subtilis*), Enterobacteria, Pseudomonas species (e.g., *P. aeruginosa*), *Salmonella typhimurium*, *Serratia marcescans*, *Klebsiella*, *Proteus*, *Shigella*, *Rhizobia*, *Vitreoscilla*, or *Paracoccus*. Preferably, gram-negative cells are used. More preferably, *E. coli* cells are 30 used as hosts for the invention. Preferred *E. coli* strain are strain W3110 (Bachmann, Cellular and Molecular Biology, vol. 2 (Washington, D.C.: American Society for Microbiology, 1987), pp. 1190-1219; ATCC Deposit No. 27,325) and derivatives thereof,

including strain 33D3 having genotype W3110 *•fhuA (•tonA) ptr3 lac Iq lacL8* *•ompT (nmpc-fepE) degP41 kan<sup>R</sup>* (U.S. Pat. No. 5,639,635). Of course other strains and derivatives thereof, such as *E. coli* 294 (ATCC 31,446), *E. coli* B, *E. coli* 1776 (ATCC 31,537) and *E. coli* RV308(ATCC 31,608) are also suitable. These examples are 5 illustrative rather than limiting. Methods for constructing derivatives of any of the above-mentioned bacteria having defined genotypes are known in the art and described in, for example, Bass *et al.*, *Proteins*, 8:309-314 (1990). It is, of course, necessary to select the appropriate bacteria taking into consideration replicability of the replicon in the cells of a bacterium. For example, *E. coli*, *Serratia*, or *Salmonella* species can be suitably used as the 10 host when well known plasmids such as pBR322, pBR325, pACYC177, or pKN410 are used to supply the replicon. Preferably the host cell should secrete minimal amounts of proteolytic enzymes, and additional protease inhibitors may desirably be incorporated in the cell culture.

### Antibody Production

15 Host cells are transformed with the above-described expression vectors and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

Transformation means introducing DNA into the prokaryotic host so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant.

20 Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride is generally used for bacterial cells that contain substantial cell-wall barriers. Another method for transformation employs polyethylene glycol/DMSO. Yet another technique used is electroporation.

25 Prokaryotic cells used to produce the polypeptides of the invention are grown in media known in the art and suitable for culture of the selected host cells. Examples of suitable media include luria broth (LB) plus necessary nutrient supplements. In preferred embodiments, the media also contains a selection agent, chosen based on the construction of the expression vector, to selectively permit growth of prokaryotic cells containing the 30 expression vector. For example, ampicillin is added to media for growth of cells expressing ampicillin resistant gene.

Any necessary supplements besides carbon, nitrogen, and inorganic phosphate sources may also be included at appropriate concentrations introduced alone or as a mixture with another supplement or medium such as a complex nitrogen source. Optionally the culture medium may contain one or more reducing agents selected from the group 5 consisting of glutathione, cysteine, cystamine, thioglycollate, dithioerythritol and dithiothreitol.

The prokaryotic host cells are cultured at suitable temperatures. For *E. coli* growth, for example, the preferred temperature ranges from about 20°C to about 39°C, more preferably from about 25°C to about 37°C, even more preferably at about 30°C. The pH of 10 the medium may be any pH ranging from about 5 to about 9, depending mainly on the host organism. For *E. coli*, the pH is preferably from about 6.8 to about 7.4, and more preferably about 7.0.

If an inducible promoter is used in the expression vector of the invention, protein expression is induced under conditions suitable for the activation of the promoter. In one 15 aspect of the invention, two PhoA promoters are used for controlling transcription of the light and heavy chains. Accordingly, the transformed host cells are cultured in a phosphate-limiting medium for induction. Preferably, the phosphate-limiting medium is the C.R.A.P medium, as described in detail below in Example 2. A variety of other inducers may be used, according to the vector construct employed, as is known in the art.

20 The expressed light and heavy chain polypeptides of the present invention are secreted into and recovered from the periplasm of the host cells. Protein recovery typically involves disrupting the microorganism, generally by such means as osmotic shock, sonication or lysis. Once cells are disrupted, cell debris or whole cells may be removed by centrifugation or filtration. The proteins may be further purified, for example, by affinity 25 resin chromatography. Alternatively, proteins can be transported into the culture media and isolated therein. Cells may be removed from the culture and the culture supernatant being filtered and concentrated for further purification of the proteins produced. The expressed polypeptides can be further isolated and identified using commonly known methods such as polyacrylamide gel electrophoresis (PAGE) and Western blot assay.

30 In one aspect of the invention, the antibody production is conducted in large quantity by a fermentation process. Various large-scale fed-batch fermentation procedures are available for production of recombinant proteins. Large-scale fermentations have at

least 1000 liters of capacity, preferably about 1,000 to 100,000 liters of capacity. These fermentors use agitator impellers to distribute oxygen and nutrients, especially glucose (the preferred carbon/energy source). Small scale fermentation refers generally to fermentation in a fermentor that is no more than approximately 100 liters in volumetric capacity, and can 5 range from about 1 liter to about 100 liters.

In a fermentation process, induction of protein expression is typically initiated after the cells have been grown under suitable conditions to a desired density, e.g., an OD<sub>550</sub> of about 180-220, at which stage the cells are in the early stationary phase. A variety of inducers may be used, according to the vector construct employed, as is known in the art 10 and described above. Cells may be grown for shorter periods prior to induction. Cells are usually induced for about 12-50 hours, although longer or shorter induction time may be used.

To improve the production yield and quality of the polypeptides of the invention, various fermentation conditions can be modified. For example, to improve the proper 15 assembly and folding of the secreted antibody polypeptides, additional vectors overexpressing chaperone proteins, such as Dsb proteins (DsbA, DsbB, DsbC, DsbD and or DsbG) or FkpA (a peptidylprolyl cis,trans-isomerase with chaperone activity) can be used to co-transform the host prokaryotic cells. The chaperone proteins have been demonstrated to facilitate the proper folding and solubility of heterologous proteins produced in bacterial 20 host cells. Chen et al. (1999) *J Bio Chem* 274:19601-19605; Georgiou et al., U.S. Patent No. 6,083,715; Georgiou et al., U.S. Patent No. 6,027,888; Bothmann and Pluckthun (2000) *J. Biol. Chem.* 275:17100-17105; Ramm and Pluckthun (2000) *J. Biol. Chem.* 275:17106-17113; Arie et al. (2001) *Mol. Microbiol.* 39:199-210. Sufficient disulfide 25 bonds are particularly important for the formation and folding of full length, bivalent antibodies having two heavy chains and two light chains.

To minimize proteolysis of expressed heterologous proteins (especially those that are proteolytically sensitive), certain host strains deficient for proteolytic enzymes can be used for the present invention. For example, host cell strains may be modified to effect 30 genetic mutation(s) in the genes encoding known bacterial proteases such as Protease III, OmpT, DegP, Tsp, Protease I, Protease Mi, Protease V, Protease VI and combinations thereof. Some *E. coli* protease-deficient strains are available and described in, for example,

Joly et al. (1998), *supra*; Georgiou et al., U.S. Patent No. 5,264,365; Georgiou et al., U.S. Patent No. 5,508,192; Hara et al., *Microbial Drug Resistance*, 2:63-72 (1996).

In a preferred embodiment, *E. coli* strains deficient for proteolytic enzymes and transformed with plasmids overexpressing one or more chaperone proteins are used as host 5 cells in the expression system of the invention. Some of these strains are further described in the Examples section below.

### Antibody Purification

In a preferred embodiment, the antibody protein produced herein is further purified to obtain preparations that are substantially homogeneous for further assays and uses.

10 Standard protein purification methods known in the art can be employed. The following procedures are exemplary of suitable purification procedures: fractionation on immunoaffinity or ion-exchange columns, ethanol precipitation, reverse phase HPLC, chromatography on silica or on a cation-exchange resin such as DEAE, chromatofocusing, SDS-PAGE, ammonium sulfate precipitation, and gel filtration using, for example, 15 Sephadex G-75.

In one aspect, Protein A immobilized on a solid phase is used for immunoaffinity purification of the full length antibody products of the invention. Protein A is a 41kD cell wall protein from *Staphylococcus aureas* which binds with a high affinity to the Fc region of antibodies. Lindmark et al (1983) *J. Immunol. Meth.* 62:1-13. The solid phase to which 20 Protein A is immobilized is preferably a column comprising a glass or silica surface, more preferably a controlled pore glass column or a silicic acid column. In some applications, the column has been coated with a reagent, such as glycerol, in an attempt to prevent nonspecific adherence of contaminants.

As the first step of purification, the preparation derived from the cell culture as 25 described above is applied onto the Protein A immobilized solid phase to allow specific binding of the full length antibody to Protein A. The solid phase is then washed to remove contaminants non-specifically bound to the solid phase. Finally the full length antibody is recovered from the solid phase by elution.

### Activity Assays

30 The full length, aglycosylated antibody of the present invention can be characterized for its physical/chemical properties and biological functions by various assays known in the

art. In one aspect of the invention, it is important to compare the antibody made in the prokaryotic host cells of the present invention to similar antibodies made in other expression systems, such as different expression vector designs or different host cell systems. Particularly, the quantity of the full length antibody expressed by the separate-  
5 cistron vector of the present invention can be compared to those expressed by various polycistronic vectors. Methods for protein quantification are well known in the art. For example, samples of the expressed proteins can be compared for their quantitative intensities on a Coomassie-stained SDS-PAGE. Alternatively, the specific band(s) of interest (e.g., the full length band) can be detected by, for example, western blot gel  
10 analysis and/or AME5-RP assay.

The purified full length antibody can be further characterized by a series of assays including, but not limited to, N-terminal sequencing, amino acid analysis, non-denaturing size exclusion high pressure liquid chromatography (HPLC), mass spectrometry, ion exchange chromatography and papain digestion.

15 In certain embodiments of the invention, the full length antibody produced herein is analyzed for its biological activity. Preferably, the antibody of the present invention is tested for its antigen binding activity. The antigen binding assays that are known in the art and can be used herein include without limitation any direct or competitive binding assays using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked  
20 immnosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, fluorescent immunoassays, and protein A immunoassays. An exemplary antigen binding assay is provided below in the Examples section.

In one embodiment, the present invention contemplates a full length antibody that is  
25 aglycosylated. The unique features of the antibody (i.e., having an intact Fc region, yet lacking effector functions) make it a desired candidate for many applications in which the half life of the antibody *in vivo* is important yet the effector functions (i.e., complement and ADCC) are unnecessary or deleterious. In certain embodiments, the Fc activities of the produced full length antibody are measured to ensure that only the desirable properties are maintained. For example, Fc receptor (FcR) binding assays can be conducted to ensure that  
30 the antibody lacks FcγR1 binding (hence lacks ADCC toxicity), but retains FcRn binding ability. C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. In vitro and *in vivo* cytotoxicity assays can be

conducted to confirm the depletion of CDC and or ADCC activities. Techniques for carrying out these assays are known in the art. Exemplary procedure details are provided in the Examples section.

### Humanized Antibodies

5 The present invention encompasses humanized antibodies. Various methods for humanizing non-human antibodies are known in the art. Preferably, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially 10 performed following the method of Winter and co-workers (Jones *et al.* (1986) *Nature* 321:522-525; Riechmann *et al.* (1988) *Nature* 332:323-327; Verhoeyen *et al.* (1988) *Science* 239:1534-1536), by substituting hypervariable region sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) wherein substantially less than an 15 intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some hypervariable region residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

20 The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicity. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework for the humanized antibody (Sims *et al.* (1993) *J. Immunol.* 151:2296; Chothia 25 *et al.* (1987) *J. Mol. Biol.* 196:901. Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter *et al.* (1992) *Proc. Natl. Acad. Sci. USA*, 89:4285; Presta *et al.* (1993) *J. Immunol.*, 151:2623.

30 It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the

parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional

5 conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, *i.e.*, the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody

10 characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the hypervariable region residues are directly and most substantially involved in influencing antigen binding.

### Antibody Variants

Amino acid sequence modification(s) of the antibodies described herein are

15 contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of the antibody are prepared by introducing appropriate nucleotide changes into the antibody nucleic acid, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequences of the

20 antibody. Any combination of deletion, insertion, and substitution is made to arrive at the final construct, provided that the final construct possesses the desired characteristics. The amino acid alterations may be introduced in the subject antibody amino acid sequence at the time that sequence is made.

A useful method for identification of certain residues or regions of the antibody

25 that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (1989) *Science*, 244:1081-1085. Here, a residue or group of target residues are identified (*e.g.*, charged residues such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine) to affect the interaction of the amino acids with antigen. Those amino acid

30 locations demonstrating functional sensitivity to the substitutions then are refined by introducing further or other variants at, or for, the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the

mutation *per se* need not be predetermined. For example, to analyze the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed full length antibodies are screened for the desired activity.

5 Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue or the antibody fused to a cytotoxic polypeptide. Other insertional variants of the antibody  
10 molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

Another type of variant is an amino acid substitution variant. These variants have at least one amino acid residue in the antibody molecule replaced by a different residue. The sites of greatest interest for substitutional mutagenesis include the hypervariable  
15 regions, but FR alterations are also contemplated. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". If such substitutions result in a change in biological activity, then more substantial changes, denominated "exemplary substitutions" in Table 1, or as further described below in reference to amino acid classes, may be introduced and the products screened.

20 **Table 1**

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; asp, lys; arg	gln
Asp (D)	glu; asn	glu
Cys (C)	ser; ala	ser
Gln (Q)	asn; glu	asn
Glu (E)	asp; gln	asp
Gly (G)	ala	ala
His (H)	asn; gln; lys; arg	arg

Ile (I)	leu; val; met; ala; phe; norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	tyr
Pro (P)	ala	ala
Ser (S)	thr; cys	cys
Thr (T)	ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala; norleucine	leu

Substantial modifications in the biological properties of the antibody are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for 5 example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- 10 (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these 15 classes for another class.

Any cysteine residue not involved in maintaining the proper conformation of the antibody also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability.

A particularly preferred type of substitutational variant involves substituting one or more hypervariable region residues of a parent antibody (*e.g.* a humanized or human antibody). Generally, the resulting variant(s) selected for further development will have improved biological properties relative to the parent antibody from which they are

5 generated. A convenient way for generating such substitutational variants involves affinity maturation using phage display. Briefly, several hypervariable region sites (*e.g.* 6-7 sites) are mutated to generate all possible amino substitutions at each site. The full length antibodies thus generated are displayed from filamentous phage particles as fusions to the gene III product of M13 packaged within each particle. The phage-displayed variants are

10 then screened for their biological activity (*e.g.* binding affinity) as herein disclosed. In order to identify candidate hypervariable region sites for modification, alanine scanning mutagenesis can be performed to identify hypervariable region residues contributing significantly to antigen binding. Alternatively, or additionally, it may be beneficial to analyze a crystal structure of the antigen-antibody complex to identify contact points

15 between the antibody and antigen. Such contact residues and neighboring residues are candidates for substitution according to the techniques elaborated herein. Once such variants are generated, the panel of variants is subjected to screening as described herein and antibodies with superior properties in one or more relevant assays may be selected for further development.

20 Nucleic acid molecules encoding amino acid sequence variants of the antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a

25 non-variant version of the antibody.

It may be desirable to introduce one or more amino acid modifications in an Fc region of the full length antibody of the invention, thereby generating a Fc region variant. The Fc region variant may comprise a human Fc region sequence (*e.g.*, a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (*e.g.* a substitution) at one or more amino acid positions.

In one embodiment, the Fc region variant may display altered neonatal Fc receptor (FcRn) binding affinity. Such variant Fc regions may comprise an amino acid modification

at any one or more of amino acid positions 238, 252, 253, 254, 255, 256, 265, 272, 286, 288, 303, 305, 307, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 386, 388, 400, 413, 415, 424, 433, 434, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat. Fc region variants with  
5 reduced binding to an FcRn may comprise an amino acid modification at any one or more of amino acid positions 252, 253, 254, 255, 288, 309, 386, 388, 400, 415, 433, 435, 436, 439 or 447 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat. The above-mentioned Fc region variants may, alternatively, display increased binding to FcRn and comprise an amino acid modification at any one or  
10 more of amino acid positions 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

The Fc region variant with reduced binding to an Fc $\gamma$ R may comprise an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

For example, the Fc region variant may display reduced binding to an Fc $\gamma$ RI and comprise an amino acid modification at any one or more of amino acid positions 238, 265, 269, 270, 327 or 329 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

The Fc region variant may display reduced binding to an Fc $\gamma$ RII and comprise an amino acid modification at any one or more of amino acid positions 238, 265, 269, 270, 292, 294, 295, 298, 303, 324, 327, 329, 333, 335, 338, 373, 376, 414, 416, 419, 435, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

The Fc region variant of interest may display reduced binding to an Fc $\gamma$ RIII and comprise an amino acid modification at one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 293, 294, 295, 296, 301, 303, 322, 327, 329, 338, 340, 373, 376, 382, 388, 389, 416, 434, 435 or 437 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

Fc region variants with altered (*i.e.* improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC) are described in WO99/51642. Such variants may comprise an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331, 333 or 334 of the Fc region. See, also, Duncan & Winter *Nature* 322:738-40 (1988); US Patent No. 5,648,260; US Patent No. 5,624,821; and WO94/29351 concerning Fc region variants.

**Immunoconjugates**

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent (as defined and described herein above), toxin (*e.g.* a small molecule toxin or an enzymatically active toxin of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof), or a radioactive isotope (*i.e.*, a radioconjugate).

Conjugates of an antibody and one or more small molecule toxins, such as a calicheamicin, a maytansine (U.S. Patent No. 5,208,020), a trichothene, and CC1065 are also contemplated herein.

In one preferred embodiment of the invention, the antibody is conjugated to one or more maytansine molecules (*e.g.* about 1 to about 10 maytansine molecules per antibody molecule). Maytansine may, for example, be converted to May-SS-Me which may be reduced to May-SH3 and reacted with modified antibody (Chari *et al. Cancer Research* 52: 127-131 (1992)) to generate a maytansinoid-antibody immunoconjugate.

Another immunoconjugate of interest comprises an antibody conjugated to one or more calicheamicin molecules. The calicheamicin family of antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. Structural analogues of calicheamicin which may be used include, but are not limited to,  $\gamma_1^1$ ,  $\alpha_2^1$ ,  $\alpha_3^1$ , N-acetyl- $\gamma_1^1$ , PSAG and  $\theta^1$  (Hinman *et al. Cancer Research* 53: 3336-3342 (1993) and Lode *et al. Cancer Research* 58: 2925-2928 (1998)). See, also, US Patent Nos. 5,714,586; 5,712,374; 5,264,586; and 5,773,001.

Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins

(PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the trichothecenes. See, for example, WO 93/21232 published October 28, 1993.

The present invention further contemplates an immunoconjugate formed between 5 an antibody and a compound with nucleolytic activity (e.g. a ribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

A variety of radioactive isotopes are available for the production of radioconjugated antibodies. Examples include At<sup>211</sup>, I<sup>131</sup>, I<sup>125</sup>, Y<sup>90</sup>, Re<sup>186</sup>, Re<sup>188</sup>, Sm<sup>153</sup>, Bi<sup>212</sup>, P<sup>32</sup> and radioactive isotopes of Lu.

10       Conjugates of the antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido 15 compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al. Science* 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene 20 triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026. The linker may be a "cleavable linker" facilitating release of the cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, dimethyl linker or disulfide-containing linker (Chari *et al. Cancer Research* 52: 127-131 (1992)) may be used.

25       Alternatively, a fusion protein comprising the antibody and cytotoxic agent may be made, e.g. by recombinant techniques or peptide synthesis.

In yet another embodiment, the antibody may be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the 30 circulation using a clearing agent and then administration of a "ligand" (e.g. avidin) which is conjugated to a cytotoxic agent (e.g. a radionucleotide).

## Antibody Derivatives

The antibodies and antibody variants of the present invention can be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. Preferably, the moieties suitable for derivatization of the antibody are water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymers are attached, they can be the same or different molecules. In general, the number and or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions.

In general, the full length antibody produced by the prokaryotic expression system described herein is aglycosylated and lacks the effector activities of the Fc region. In some instances, it may be desirable to at least partially restore one or more effector functions of the native full length antibody. Accordingly, the present invention contemplates a method for restoring the effector function(s) by attaching suitable moieties to identified residue sites in the Fc region of the aglycosylated full length antibody. A preferred moiety for this purpose is PEG, although other carbohydrate polymers can also be used. Pegylation may be carried out by any of the pegylation reactions known in the art. See, for example, EP 0401384; EP 0154316; WO 98/48837. In one embodiment, cysteine residues are first substituted for residues at identified positions of the antibody, such as those positions wherein the antibody or antibody variant is normally glycosylated or those positions on the surface of the antibody. Preferably, the cysteine is substituted for residue(s) at one or more positions 297, 298, 299, 264, 265 and 239 (numbering according to the EU index as in

Kabat). After expression, the cysteine substituted antibody variant can have various forms of PEG (or pre-synthesized carbohydrate) chemically linked to the free cysteine residues.

### Pharmaceutical Formulations

Therapeutic formulations of the full length antibody are prepared for storage by mixing the antibody having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (*Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980)), in the form of aqueous solutions, lyophilized or other dried formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, histidine and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (*e.g.*, Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule, respectively, in colloidal drug delivery systems (for example, liposomes, 30 albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences* 16th edition, Osol, A. Ed. (1980).

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers

5 containing the full length antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid

10 copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or

15 aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing

20 from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

### Uses

An antibody of the present invention may be used, for example, to purify, detect, and target a specific polypeptide it recognizes, including both *in vitro* and *in vivo*

25 diagnostic and therapeutic methods.

In one aspect, an antibody of the invention can be used in immunoassays for qualitatively and quantitatively measuring specific antigens in biological samples. Conventional methods for detecting antigen-antibody binding includes, for example, an enzyme linked immunosorbent assay (ELISA), an radioimmunoassay (RIA) or tissue

30 immunohistochemistry. Many methods may use a label bound to the antibody for detection purposes. The label used with the antibody is any detectable functionality that does not interfere with its binding to antibody. Numerous labels are known, including the

radioisotopes  $^{32}\text{P}$ ,  $^{32}\text{S}$ ,  $^{14}\text{C}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ , and  $^{131}\text{I}$ , fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, .beta.-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, lactoperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, imaging radionuclides (such as Technecium) and the like.

10 Conventional methods are available to bind these labels covalently to the antibody polypeptides. For instance, coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imides, bis-diazotized benzidine, and the like may be used to tag the antibodies with the above-described fluorescent, chemiluminescent, and enzyme labels. See, for example, U.S. Pat. No. 3,940,475 (fluorimetry) and U.S. Pat. No. 3,645,090 (enzymes); Hunter et al. *Nature* 144: 945 (1962); David et al. *Biochemistry* 13:1014-1021 (1974); Pain et al. *J. Immunol. Methods* 40:219-230 (1981); and Nygren *Histochem. and Cytochem* 30:407-412 (1982). Preferred labels herein are enzymes such as horseradish peroxidase and alkaline phosphatase. The conjugation of such label, including the enzymes, to the antibody polypeptide is a standard manipulative procedure for one of ordinary skill in 20 immunoassay techniques. See, for example, O'Sullivan et al., "Methods for the Preparation of Enzyme-antibody Conjugates for Use in Enzyme Immunoassay," in *Methods in Enzymology*, ed. J. J. Langone and H. Van Vunakis, Vol. 73 (Academic Press, New York, N.Y., 1981 ), pp. 147-166. Such bonding methods are suitable for use with the antibody polypeptides of this invention.

25 Alternative to labeling the antibody, antigen can be assayed in biological fluids by a competition immunoassay utilizing a competing antigen standard labeled with a detectable substance and an unlabeled antibody. In this assay, the biological sample, the labeled antigen standards and the antibody are combined and the amount of labeled antigen standard bound to the unlabeled antibody is determined. The amount of tested antigen in 30 the biological sample is inversely proportional to the amount of labeled antigen standard bound to the antibody.

In one aspect, the aglycosylated full length antibody of the invention is particularly useful to detect and profile expressions of specific surface antigens *in vitro* or *in vivo*. As discussed before, the aglycosylated full length antibody does not exert effector functions (i.e., ADCC or CDC activity). Therefore, when the antibody binds to the cell surface antigen, it will not initiate undesirable cytotoxic events. The surface antigen can be specific to a particular cell or tissue type, therefore serving as a marker of the cell or tissue type. Preferably, the surface antigen marker is differentially expressed at various differentiation stages of particular cell or tissue types. The full length antibody directed against such surface antigen can thus be used for the screening of cell or tissue populations expressing the marker. For example, the antibody of the invention can be used for the screening and isolation of stem cells such as embryonic stem cells, hematopoietic stem cells and mesenchymal stem cells. The antibody of the invention can also be used to detect tumor cells expressing tumor-associated surface antigens such HER2, HER3 or HER4 receptors.

A full length antibody of the invention may be used as an affinity purification agent. In this process, the full length antibody is immobilized on a solid phase such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody is contacted with a sample containing the antigen to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the antigen to be purified, which is bound to the immobilized full length antibody. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the antigen from the full length antibody.

The antibodies of the invention can be used as an antagonist to partially or fully block the specific antigen activity both *in vitro* and *in vivo*. Moreover, at least some of the antibodies of the invention, can neutralize antigen activity from other species. Accordingly, the antibodies of the invention can be used to inhibit a specific antigen activity, e.g., in a cell culture containing the antigen, in human subjects or in other mammalian subjects having the antigen with which an antibody of the invention cross-reacts (e.g. chimpanzee, baboon, marmoset, cynomolgus and rhesus, pig or mouse). In one embodiment, the antibody of the invention can be used for inhibiting antigen activities by contacting the antibody with the antigen such that antigen activity is inhibited. Preferably, the antigen is a human protein molecule.

In another embodiment, an antibody of the invention can be used in a method for inhibiting an antigen in a subject suffering from a disorder in which the antigen activity is detrimental, comprising administering to the subject an antibody of the invention such that the antigen activity in the subject is inhibited. Preferably, the antigen is a human protein

5 molecule and the subject is a human subject. Alternatively, the subject can be a mammal expressing the antigen with which an antibody of the invention binds. Still further the subject can be a mammal into which the antigen has been introduced (e.g., by administration of the antigen or by expression of an antigen transgene). An antibody of the invention can be administered to a human subject for therapeutic purposes. Moreover, an

10 antibody of the invention can be administered to a non-human mammal expressing an antigen with which the antibody cross-reacts (e.g., a primate, pig or mouse) for veterinary purposes or as an animal model of human disease. Regarding the latter, such animal models may be useful for evaluating the therapeutic efficacy of antibodies of the invention (e.g., testing of dosages and time courses of administration). Blocking antibodies of the

15 invention that are therapeutically useful include, for example but not limited to, anti-VEGF, anti-IgE, anti-CD11 and anti-tissue factor antibodies. The antibodies of the invention can be used to diagnose, treat, inhibit or prevent diseases, disorders or conditions associated with abnormal expression and or activity of one or more antigen molecules, including but not limited to malignant and benign tumors; non-leukemias and lymphoid

20 malignancies; neuronal, glial, astrocytal, hypothalamic and other glandular, macrophagal, epithelial, stromal and blastocoelic disorders; and inflammatory, angiogenic and immunologic disorders.

In one aspect, the blocking antibody of the invention is specific to a ligand antigen, and inhibits the antigen activity by blocking or interfering with the ligand-receptor

25 interaction involving the ligand antigen, thereby inhibiting the corresponding signal pathway and other molecular or cellular events. The invention also features receptor-specific antibodies which do not necessarily prevent ligand binding but interfere with receptor activation, thereby inhibiting any responses that would normally be initiated by the ligand binding. The invention also encompasses antibodies that either preferably or

30 exclusively bind to ligand-receptor complexes. The antibody of the invention can also act as an agonist of a particular antigen receptor, thereby potentiating, enhancing or activating either all or partial activities of the ligand-mediated receptor activation.

In certain embodiments, an immunoconjugate comprising the antibody conjugated with a cytotoxic agent is administered to the patient. Preferably, the immunoconjugate and/or antigen to which it is bound is/are internalized by the cell, resulting in increased therapeutic efficacy of the immunoconjugate in killing the target cell to which it binds. In a 5 preferred embodiment, the cytotoxic agent targets or interferes with nucleic acid in the target cell. Examples of such cytotoxic agents include any of the chemotherapeutic agents noted herein (such as a maytansinoid or a calicheamicin), a radioactive isotope, or a ribonuclease or a DNA endonuclease.

Antibodies of the present invention can be used either alone or in combination with 10 other compositions in a therapy. For instance, the antibody may be co-administered with another antibody, chemotherapeutic agent(s) (including cocktails of chemotherapeutic agents), other cytotoxic agent(s), anti-angiogenic agent(s), cytokines, and/or growth inhibitory agent(s). Where the full length antibody inhibits tumor growth, it may be particularly desirable to combine the full length antibody with one or more other 15 therapeutic agent(s) which also inhibits tumor growth. For instance, anti-VEGF antibodies blocking VEGF activities may be combined with anti-ErbB antibodies (*e.g.* HERCEPTIN® anti-HER2 antibody) in a treatment of metastatic breast cancer. Alternatively, or additionally, the patient may receive combined radiation therapy (*e.g.* external beam 20 irradiation or therapy with a radioactive labeled agent, such as an antibody). Such combined therapies noted above include combined administration (where the two or more agents are included in the same or separate formulations), and separate administration, in which case, administration of the full length antibody can occur prior to, and/or following, administration of the adjunct therapy or therapies.

The full length antibody (and adjunct therapeutic agent) is/are administered by any 25 suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In addition, the full length antibody is suitably administered by pulse infusion, particularly with declining doses of the antibody. Preferably the dosing is given 30 by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.

The full length antibody composition of the invention will be formulated, dosed,

and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The full length antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of full length antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.

For the prevention or treatment of disease, the appropriate dosage of the full length antibody (when used alone or in combination with other agents such as chemotherapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the full length antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the full length antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1  $\mu$ g/kg to 15 mg/kg (e.g. 0.1mg/kg-10mg/kg) of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1  $\mu$ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. The preferred dosage of the antibody will be in the range from about 0.05mg/kg to about 10mg/kg. Thus, one or more doses of about 0.5mg/kg, 2.0mg/kg, 4.0mg/kg or 10mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. An exemplary dosing regimen comprises administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the

antibody. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

### Articles of Manufacture

In another embodiment of the invention, an article of manufacture containing

5 materials useful for the treatment of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a

10 sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is a full length antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice, such as cancer. Moreover, the article of manufacture may comprise (a) a first container with a composition

15 contained therein, wherein the composition comprises a full length antibody; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the first and second antibody compositions can be used to treat cancer. Alternatively, or additionally, the article of

20 manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

25 The following examples are intended merely to illustrate the practice of the present invention and are not provided by way of limitation. The disclosures of all patent and scientific literatures cited herein are expressly incorporated in their entirety by reference.

### EXAMPLES

#### **Example 1. Construction of Expression Vectors**

30 Various expression vectors were made for the expression of antibodies specific to tissue factor (anti-TF antibody) and antibodies specific to vascular endothelial cell growth

factor (anti-VEGF antibody). For each vector construction, an expression cassette was cloned into the framework of the *E. coli* plasmid pBR322 at the EcoRI site. Sutcliffe (1978) *Cold Spring Harbor Symp. Quant. Biol.* 43:77-90. Each expression cassette contains at least the following components: (1) a *phoA* promoter for the control of transcription; (2) a Shine-Dalgarno sequence from the *E. coli* *trp* or the heat stable enterotoxin II (STII) gene, or a combination of both, for translation initiation; and (3) a  $\lambda t_0$  terminator to end transcription. The basic components of bacterial expression cassettes are known in the art and have been described in, for example, Kikuchi et al., *Nucleic Acids Res.* 9(21):5671-5678 (1981) (for *phoA* promoter); Scholtissek and Grosse, *Nucleic Acids Res.* 15:3185 (1987) (for  $\lambda t_0$  terminator); Yanofsky et al., *Nucleic Acids Res.* 9:6647-6668 (1981) (for *trp*); Picken et al., *Infect. Immun.* 42:269-275 (1983) (for STII); and Chang et al., *Gene* 55:189-196 (1987) (for combination use of *trp* and STII Shine-Dalgarno sequence). Additionally, the STII signal sequence or silent codon variants thereof precedes the coding sequence for light or heavy chain and directs the secretion of the polypeptide into periplasm. Picken et al., *Infect. Immun.* 42:269-275 (1983); Simmons and Yansura, *Nature Biotechnology* 14:629-634 (1996).

### Polycistronic Vectors

In order to illustrate the enhanced properties of the separate cistron systems of the present invention, several polycistronic vectors for full length antibodies were constructed for comparisons. In a polycistronic vector, the two cistrons for light and heavy chain genes are under the transcriptional control of one single PhoA promoter.

The initial polycistronic vector for anti-TF antibody expression, pxTFPV, was constructed using the expression cassette of a previously published vector, pAK19, which was for antibody fragment Fab' expression. Carter et al. (1992) *Bio/Technology* 10:12-16. The structure of the original pAK19 and the construction of the full length version pxTFPV are illustrated in Figure 1. The expression cassette contains, from 5' to 3' end, a PhoA promoter, the cistron for light chain, the cistron for heavy chain and a transcription terminator  $\lambda t_0$ . The distance between the light chain stop codon and the start of the STII signal sequence preceding the heavy chain is 81 base pairs. To construct a polycistronic anti-VEGF vector, the coding sequences for anti-VEGF light and heavy chains were substituted for the coding sequences of anti-TF light and heavy chains in pxTFPV. The anti-VEGF expression cassette was further modified by deleting the ~50 bp HindIII

fragment upstream of the PhoA promoter and several nucleotide changes were also made in the untranslated region upstream of the heavy chain Shine-Dalgarno sequence. The resulting polycistronic vector for anti-VEGF is named pY0317.Fab\_CH3.

Several additional polycistronic anti-TF constructs, paTF20, paTF30, paTF40, 5 paTF90, paTF110, paTF100, paTF120, were similarly made. The expression cassette sequences of these polycistronic plasmids differ from that of pxTFPV mainly in the 5' untranslated region and in the region preceding the secretion signal sequence for the heavy chain. Additionally, depending upon the construct, silent codon differences also exist in the STII signal sequence between pxTFPV and some of the additional polycistronic 10 plasmids. Simmons and Yansura, *Nature Biotechnology*, 14:629-634 (1996).

### Separate Cistron Vectors

To practice the present invention, vectors with separate cistrons were designed to provide independent expression of the immunoglobulin light and heavy chain genes. In such vectors, the cistron unit for each chain is under the control of its own PhoA promoter 15 and is followed by a  $\lambda t_0$  terminator. Furthermore, each cistron unit comprises a TIR upstream of the coding sequence for light or heavy chain. The construction of a separate cistron vector is illustrated in Figure 7. The expression cassette comprises, from 5' to 3', a first PhoA promoter followed by the cistron for light chain (TIR-L + Light Chain) and the first  $\lambda t_0$  terminator, and a second PhoA promoter followed by the cistron for heavy chain 20 (TIR-H + Heavy Chain) and the second  $\lambda t_0$  terminator. Both TIR-L and TIR-H further contain therein an STII secretion signal sequence or its variant. The expression cassette sequences of paTF50 (for anti-TF; SEQ ID NO:1) and pxVG2AP11 (for anti-VEGF; SEQ ID NO:2) are provided in Figures 20 and 21, respectively. Additional separate cistron 25 vectors for anti-TF, paTF70, paTF60, paTF80, paTF130, paTF140, and pxTF2AP77 represent various combinations of TIR strengths for light and heavy chain translations and differ from paTF50 with respect to silent codon changes in the STII signal sequence, as previously described. Simmons and Yansura, *Nature Biotechnology*, 14:629-634 (1996).

### Example 2. *E. coli* Expression of Full Length Antibodies Using Polycistronic Vectors

Full length antibodies were first made in *E. coli* using polycistronic vectors derived 30 from a published vector, pAK19, according to the methods described in Example 1. Small

scale inductions were first performed to evaluate and compare the expression levels obtained with the various constructs.

### Materials and Methods

For small scale expression of each construct, the *E. coli* strain 33D3 (W3110 •*fhuA* •*tonA*) *ptr3 lac Iq lacL8* •*ompT*•(*nmpC-fepE*) *degP41 kan*<sup>R</sup>) was used as host cells. Following transformation, selected transformant picks were inoculated into 5 ml Luria-Bertani medium supplemented with carbenicillin (50 ug/ml) and grown at 30<sup>0</sup>C on a culture wheel overnight. Each culture was then diluted (1:50 or 1:100) into C.R.A.P. phosphate-limiting media (3.57g (NH4)2SO4, 0.71g NaCitrate-2H2O, 1.07g KCl, 5.36g Yeast Extract (certified), 5.36g HycaseSF-Sheffield, adjusted pH with KOH to 7.3, qs to 872 ml with SQ H2O and autoclaved; cool to 55<sup>0</sup> C and supplemented with 110 ml 1M MOPS pH 7.3, 11 ml 50% glucose, 7 ml 1M MgSO4). Carbenicillin was then added to the induction culture at a concentration of 50ug/ml and the culture was grown for approximately 24 hours at 30<sup>0</sup> C on a culture wheel. Unless otherwise noted, all shake flask inductions were performed in a 2 ml volume.

Non-reduced whole cell lysates from induced cultures were prepared as follows: (1) 1 OD<sub>600</sub> -ml pellets were centrifuged in a microfuge tube; (2) each pellet was resuspended in 90 ul TE (10mM Tris pH 7.6, 1mM EDTA); (3) 10 ul of 100 mM iodoacetic acid (Sigma I-2512) was added to each sample to block any free cysteines and prevent disulfide shuffling; (4) 20 ul of 10% SDS was added to each sample. The samples were vortexed, heated to about 90<sup>0</sup> C for ~ 3 minutes and then vortexed again. After the samples had cooled to room temperature, ~ 750-1000 ul acetone was added to precipitate the protein. The samples were vortexed and left at room temperature for about 15 minutes. Following centrifugation for 5 minutes in a microcentrifuge, the supernatant of each sample was aspirated off and each protein pellet was resuspended in 50 ul dH<sub>2</sub>O + 50 ul 2X NOVEX sample buffer. The samples were then heated for ~3-5 minutes at about 90<sup>0</sup> C, vortexed well and allowed to cool to room temperature. A final 5 minute centrifugation was then done and the supernatants were transferred to clean tubes.

Reduced samples were prepared by following steps similar to what is described above for non-reduced samples, except that 10 ul of 1M DTT was added to the cell resuspension solution in Step (2) and the addition of IAA was omitted in Step (3).

Reducing agent was also added to a concentration of 100 mM when the protein precipitate was resuspended in 2X sample buffer + dH<sub>2</sub>O.

Following preparation, 5-10 ul of each sample was loaded onto a 10 well, 1.0 mm NOVEX manufactured 12% Tris-Glycine SDS-PAG and electrophoresed at ~120 volts for 5 1.5 - 2 hours. The resulting gels were then either stained with Coomassie Blue or used for Western blot analysis.

For Western blot analysis, the SDS-PAGE gels were electroblotted onto a nitrocellulose membrane (NOVEX). The membrane was then blocked using a solution of 1X NET (150 mM NaCl, 5 mM EDTA, 50 mM Tris pH 7.4, 0.05% Triton X-100) + 0.5% 10 gelatin for approximately 30 min. - 1 hour rocking at room temperature. Following the blocking step, the membrane was placed in a solution of 1X NET + 0.5% gelatin + anti-Fab antibody (peroxidase-conjugated goat IgG fraction to human IgG Fab; CAPPEL #55223). The anti-Fab antibody dilution ranged from 1:50,000 to 1:1,000,000 depending on the lot of antibody. The membrane was left in the antibody solution overnight at room 15 temperature with rocking. The next morning, the membrane was washed a minimum of 3 x 10 minutes in 1X NET + 0.5% gelatin and then 1 x 15 minutes in TBS (20 mM Tris pH 7.5, 500 mM NaCl). The protein bands bound by the anti-Fab antibody were visualized by using Amersham Pharmacia Biotech ECL detection and exposing the membrane to X-Ray film.

20 Some of the expressed protein bands were further subjected to N-terminal sequence analysis in which, following SDS-PAGE electrophoresis, samples from induced cultures were electroblotted to a PVDF membrane (Matsudaira, J. Biol. Chem. 262:10035-10038 (1987)). Appropriate PVDF bands were sequenced on an Applied Biosystems (Foster City, CA) 494HT or 494cLC sequencer equipped with a 140C or 140D online PTH analyzer 25 (Henzel et al., *Methods: A Companion to Methods Enzymol.* 6:239-247 (1994)).

## RESULTS

### Polycistronic Vectors Produced Limited Quantities of Full Length Antibodies

Polycistronic plasmids for anti-TF antibody (pxTFPV) and anti-VEGF antibody (pY0317.Fab\_CH3) were constructed, transformed into strain 33D3 and induced as 30 described in Example 1 and above under Methods and Materials. Non-reduced whole cell lysate samples were then prepared and analyzed by western blot. The results are shown in

Figure 2. As the arrow indicates, a small amount of apparently full length, correctly folded antibody was observed for anti-TF antibody (Lane 2), and essentially no full length band was detected in the anti-VEGF antibody sample (Lane 3). Reduced samples were then prepared, separated by SDS-PAGE and transferred to a PVDF membrane. The induced 5 protein bands for both anti-TF and anti-VEGF antibodies were then cut out and submitted for N-terminal amino acid analysis. The results revealed a mixture of processed mature protein and unprocessed precursor protein (in which the secretion signal sequence was not cleaved off) for both constructs. Thus, the polycistronic vectors pxTFPV and pY0317.Fab\_CH3 failed to direct significant secretion and assembly of full length anti-TF 10 or anti-VEGF antibodies.

To address the problem of inefficient secretion, additional polycistronic vectors were made with modulated TIR strength combinations for light and heavy chain, as illustrated in Figure 3. The purpose of this experiment was to determine the translational levels that would achieve better secretion of light and heavy chains. The different 15 combinations of TIR strengths could also be used to determine the preferred expression ratio of light to heavy chain for maximum accumulation of full length antibody. All of the constructs were designed and constructed according to the teachings in Example 1. The following constructs with various TIR strength combinations were constructed: paTF20 (1-light chain, 1-heavy chain), paTF30 (3-light, 1-heavy), paTF40 (1-light, 3-heavy), paTF90 (3-light, 3-heavy), paTF100 (3-light, 7-heavy), paTF110 (7-light, 3-heavy), paTF120 (7-light, 7-heavy). The numbers in the parenthesis represent the TIR relative strength for 20 light or heavy chain, as described in Simmons et al., *Nature Biotechnol.* 14:629-634(1996), and in U.S. Patent No. 5,840,523.

Western blot results of expression products using polycistronic vectors with various 25 TIR strength combinations are shown in Figure 4. 4A shows samples under reduced conditions in which the separated light and heavy chains. And 4B shows samples under non-reduced conditions in which the disulfide bonds remain intact. The reduced samples clearly show a large excess of light chain over heavy chain at all TIR strength combinations, even taken into consideration the fact that light chain is more readily 30 detectable than heavy chain using this anti-Fab antibody (Figure 4A). At the highest TIR strength combination (paTF120 (7-light, 7-heavy)), a small amount of unprocessed light chain starts to accumulate, indicating that secretion is being blocked. The non-reduced

Western blot shows the accumulation of full length antibody along with several intermediate forms (Figure 4B). The maximum level of full length antibody is achieved with paTF40 (1-light, 3-heavy) followed by paTF100 (3-light, 7-heavy). Both of these constructs have relatively lower ratios of light vs. heavy chain expression as shown in 5 Figure 4A, suggesting that the level of folded full length antibody is correlated to the relative expression levels of light and heavy chains.

**Example 3. *E. coli* Expression of Full length Antibodies Using Separate Cistron Vectors**

To construct the separate cistron vectors with modulated TIR strength 10 combinations, a preferred TIR strength for secretion of each individual chain was first determined in a series of single cistron plasmids constructed to express light or heavy chain only (Figure 5). A series of single cistron plasmids with various TIRs was therefore constructed for the individual expression of both anti-TF light and heavy chains. Methods and materials used for vector construction and protein expression were similar to those 15 used for polycistronic vector expressions, which has been described in Examples 1 and 2 above.

The range of TIR strengths tested extended from a relative strength of 1 to a maximum relative strength of 13. Reduced whole cell lysates from induced cultures 20 transformed with these constructed plasmids were analyzed by SDS-PAGE and the results are shown in Fig. 6. For both heavy and light chain, levels of secreted protein increase with increasing TIR up to a relative strength of 7. Then, in the case of heavy chain, the level of mature protein decreases when the TIR relative strength is raised to 13. When a TIR relative strength of 13 is used for light chain expression, the level of mature protein remains constant; however, precursor material begins to accumulate using this construct. 25 This result suggested that for individual expression of light and heavy chain, the most preferred TIR is 7. The light and heavy chain protein bands produced using the TIR of 7 were confirmed by N-terminal amino acid analysis to be the completely processed mature form of the protein.

Once the most preferred TIR for each individual antibody chain was determined, 30 the next step involved bringing together the two cistrons onto one plasmid. The two constructs with the TIR's of 7 were combined such that expression of each gene was maintained under the control of its own PhoA promoter (Fig. 7). Following transformation

and induction, reduced whole cell lysate from this expression plasmid (pxTF2AP77) was prepared and analyzed by SDS-PAGE (Fig. 8). Four antibody-related bands were detected by Coomassie staining. These protein bands were subsequently determined by N-terminal amino acid analysis to be precursor and mature forms of both heavy and light chains.

5 Therefore, although the preferred TIR strength may have been determined for each individual chain, when the two cistrons, maintained under the control of separate promoters, were combined onto a single construct, the simultaneous co-expression of both chains resulted in inefficient protein secretion. This result suggested that the most preferred TIR combination should be determined by simultaneously altering the individual  
10 TIRs for light and heavy chains in the context of a separate cistron construct.

A series of new constructs was prepared to determine the TIR strength combinations for light and heavy in the context of a separate cistron system. The TIR series shown in Figure 9 parallels that of the polycistronic series and includes paTF50 (1-light, 1-heavy), paTF70 (3-light, 1-heavy), paTF60 (1-light, 3-heavy), paTF80 (3-light, 3-heavy), paTF130 (7-light, 3-heavy), paTF140 (3-light, 7-heavy), and pxTF2AP77 (7-light, 7-heavy). All expression inductions (2mL) were carried out side-by-side in strain 33D3. Samples were removed for SDS-PAGE separation and the Western blot results are shown in Figure 10. The reduced samples (Figure 10A) show a more even distribution of light and heavy chains compared to the results from polycistronic vectors. A small level of light  
15 chain precursor accumulates with paTF80 (3-light, 3-heavy) and paTF140 (3-light, 7-heavy), while significant amounts of light and heavy chain precursor are obvious for paTF130 (7-light, 3-heavy) and pxTF2AP77 (7-light, 7-heavy). The non-reduced samples reveal various levels of full length antibody along with intermediate species (Figure 10B). The greatest accumulation of full length antibody occurs with paTF50 (1-light, 1-heavy),  
20 and as the translation levels increase slowly up to paTF80 (3-light, 3-heavy), the levels of intermediate species rise dramatically. The two constructs with large amounts of unprocessed light and heavy chain (paTF130 and pxTF2AP77) show a sharp decrease in the levels of full length antibody as well as intermediate species. Therefore, the results  
25 suggested that for anti-TF full length antibody, the most preferred TIR combination is (1-light, 1-heavy), as represented by the plasmid paTF50.

Next, in order to further illustrate the high yield of full length antibody by the separate cistron system, expressions using the polycistronic constructs (paTF20 (1-light, 1-

heavy), paTF30 (3-light, 1-heavy) and paTF40 (1-light, 3-heavy)) and the separate cistron constructs (paTF50 (1-heavy, 1-light), paTF60 (1-light, 3-heavy), paTF70 (3-light, 1-heavy) and paTF80 (3-light, 3-heavy)) were compared side by side. The non-reduced samples clearly show a much higher production level of full length antibody and

5 intermediate species with the separate cistron system (Figure 11). As shown on the gel, the best of the polycistronic constructs, paTF40 (1-light, 3-heavy), is still inferior to each of the separate cistron constructs shown.

A similar comparison between the pAK19-derived polycistronic plasmids and the separate cistron plasmids further illustrates the advantages of this new technology for the

10 expression of full length antibodies in *E. coli*. The analysis included expression plasmids for both anti-tissue factor and anti-VEGF antibodies. With respect to the expression of anti-tissue factor, the polycistronic plasmid pxTFPV and the separate cistron plasmid paTF50 (1-light, 1-heavy) were transformed into strain 33D3 and induced in phosphate-limiting media. Non-reduced samples were prepared (IAA treated) and analyzed by

15 Coomassie-stained SDS-PAGE (Fig. 12). An induced full length antibody protein band is observed from the separate cistron sample, using only Coomassie Blue stain as a method of detection (Lane 3). This protein band was subsequently determined by N-terminal amino acid analysis to contain both anti-tissue factor light and heavy chains, as expected. No such protein band is apparent by Coomassie staining using the polycistronic plasmid (Lane 2).

20 The samples were also analyzed by western blot using a polyclonal goat anti-human Fab antibody (Fig. 13). Applying this sensitive method of detection, a small amount of full length antibody can be seen using the polycistronic plasmid (Lane 2); however, the expression level increases dramatically using the separate cistron plasmid (Lane 3).

A similar experiment comparing the expression of anti-VEGF antibody using a

25 polycistronic vector (pY0317.Fab\_CH3) and a separate cistron vector, pxVG2AP11 (1-light, 1-heavy), was also performed. The plasmids were transformed into strain 33D3 and induced in phosphate-limiting media. Non-reduced samples were prepared (IAA treated) and analyzed by Western Blot using a polyclonal goat anti-human Fab antibody (Fig. 14). Virtually no full length antibody is apparent using the polycistronic vector. Much of the

30 sample appears as an indiscreet smear (Lane 2), a pattern which appears to correlate with a very high excess of light chain expression. In contrast, when the separate cistron system was used, a distinct full length antibody protein band is observed (arrow; Lane 3). Thus,

for the expression of full length anti-VEGF, the separate cistron vector of the invention increases the expression level from essentially no detectable full length antibody to a level readily detectable by western blot.

**Example 4. Large-scale Production (Fermentation) and Purification of Full Length Antibodies Expressed in *E. coli***

Full length anti-TF and anti-VEGF antibodies were also produced in large scale, using fermentation processes. The organisms used for these fermentations include: 59A7 W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $phoA\Delta E15$   $\Delta(argF-lac)169$   $deoC$   $degP41$   $kan^S$   $ilvG^+$   $\Delta prc::kanR$   $prc$  suppressor; 43H1 W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $phoA\Delta E15$   $\Delta(argF-lac)169$   $ptr3$   $degP41$  10  $kan^S$   $\Delta ompT\Delta(nmpc-fepE)$   $ilvG^+$   $prc::kanR$   $prc$  suppressor; 33D3 W3110  $\bullet fhuA$  ( $\bullet tonA$ )  $ptr3$   $lac$   $Iq$   $lacL8$   $\bullet ompT\bullet(nmpc-fepE)$   $degP41$   $kan^R$ ; and 58H7 W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $\Delta$   $ptr3$   $\Delta ompT$   $\Delta degP$   $lac$   $Iq$   $\Delta lacY$ .

For each 10-liter fermentation, 0.5 mL of frozen stock culture (containing 10-15% DMSO) was thawed and used to inoculate a 2L shake flask containing 500 ml of LB 15 medium supplemented with either 0.5 ml of tetracycline solution (5 mg/ml) or 10 mL of ampicillin solution (2 mg/mL) and 2.5 ml 1M sodium phosphate solution. This seed culture was grown for approximately 16 hours at 30 °C with shaking and was then used to inoculate the 10-liter fermentor.

The fermentor initially contained approximately 7.0 liters of medium containing 20 1.1 g of glucose, 100 ml of 1M magnesium sulfate, 10 ml of a trace element solution (100 ml hydrochloric acid, 27 g ferric chloride hexahydrate, 8 g zinc sulfate heptahydrate, 7 g cobalt chloride hexahydrate, 7 g sodium molybdate dihydrate, 8 g cupric sulfate pentahydrate, 2 g boric acid, 5 g manganese sulfate monohydrate, in a final volume of 1 liter), either 20 ml of a tetracycline solution (5 mg/ml in ethanol) or 250 mL of an 25 ampicillin solution (2 mg/mL), 1 bag of HCD salts, (37.5 g ammonium sulfate, 19.5 g potassium phosphate dibasic, 9.75 g sodium phosphate monobasic dihydrate, 7.5 g sodium citrate dihydrate, 11.3 g potassium phosphate monobasic), 200 g of NZ Amine A (a protein hydrolysate), and 100 grams of Yeast Extract. Fermentations were performed at 30 °C with 20 slpm of air flow and were controlled at a pH of 7.0 ± 0.2 (although occasional 30 excursions beyond this range occurred in some cases). The back pressure of the fermentor was maintained at 1 bar gauge and the agitation rate was set to 650 rpm. The back pressure of the fermentor and agitation rate can also be varied to manipulate the oxygen transfer rate

in the fermentor, and, consequently, control the cellular respiration rate.

Following inoculation of the fermentor with the cell-containing medium from the shake flask, the culture was grown in the fermentor to high cell densities using a computer-based algorithm to feed a concentrated glucose solution to the fermentor. Ammonium hydroxide (58% solution) and sulfuric acid (24% solution) were also fed to the fermentor as needed to control pH. Additions of L-61 (an antifoam – others can be used) were also used in some cases to control foaming. When the culture reached a cell density of approximately 40 OD550, an additional 100 ml of 1M magnesium sulfate was added to the fermentor. Additionally, a concentrated salt feed (12.5 g ammonium sulfate, 32.5 g 5 potassium phosphate dibasic, 16.25 g sodium phosphate monobasic dihydrate, 2.5 g sodium citrate dihydrate, 18.75 g potassium phosphate monobasic, 10 ml of 2.7% ferric chloride and 10 ml of trace elements in a final volume of 1250 ml) was added to the fermentor and started at a rate of 2.5 ml/min when the culture reached approximately 20 10 OD550 and continued until approximately 1250 ml were added to the fermentation.

15 Fermentations were typically continued for 70-80 hours. During the fermentation, once the dissolved oxygen set point for the fermentation was reached, the concentrated glucose solution was fed based on the dissolved oxygen probe signal in order to control the dissolved oxygen concentration at the set point. Consequently, in this control scheme, manipulations of fermentor operating parameters such as the agitation rate or back pressure 20 which affect the oxygen transfer capacity in the fermentation correspondingly also manipulated the oxygen uptake rate or metabolic rate of the cells. A mass spectrometer was used to monitor the composition of the off-gas from the fermentations and enable the calculation of the oxygen uptake and carbon dioxide evolution rates in the fermentations.

Non-reduced soluble samples were prepared as follows: frozen, 1 mL whole broth 25 samples taken during the course of the fermentation were thawed at room temperature. 100  $\mu$ L of the thawed whole broth was added to 500  $\mu$ L of extraction buffer. (Extraction buffer: 10 mM Tris, pH 6.8, 5 mM EDTA, freshly added 0.2 mg/mL of hen egg lysozyme, and freshly prepared iodacetic acid to a final concentration of 5-10 mM.) The whole broth samples plus extraction buffer were incubated on ice for 5-10 minutes, then sonicated 2 x 30 10 pulses, then centrifuged at 4C and 14,000 rpm for 15-20 minutes. The supernatant was removed as the soluble fraction. For analysis by SDS-PAGE and immunoblots, the soluble fraction was diluted 1:4 into 2X Novex Tricine sample buffer without reducing agent. 10

$\mu$ L of this prep was loaded onto a 15 well Novex 4-12% Bis-Tris NuPage gel and electrophoresed at 200 V with MOPS buffer. The gel was then used for either an immunoblot or stained with Coomassie Blue.

Samples of the soluble fractions were submitted for analysis by an AME5-RP assay.

5 This assay is a dual column HPLC assay where the first column is an affinity column that captures light chain and the second column is a reversed-phase column. An Integral Workstation was configured in the dual column mode. The solvent reservoirs were:

10 Solvent 1A, affinity loading buffer; Solvent 1B, reversed-phase aqueous buffer and affinity elution buffer, 0.1% TFA in water; Solvent 2A, water; Solvent 2B, reversed-phase organic elution buffer, 0.09% TFA/80% acetonitrile. The first column was the affinity column (30 x 2.1 mm) containing an immobilized anti-light-chain (kappa) Fab antibody (AME5) immobilized on controlled pore glass. All procedures involving the affinity column were performed at ambient temperature. The second column was the reversed-phase column containing the polymer based POROS R220 packing material (30 x 2.1 mm). The

15 reversed-phase column temperature was maintained at 60°C.

The affinity column was equilibrated in 30% loading buffer (5ml) and a 50  $\mu$ l sample was loaded at a flow rate of 0.1 ml/min. The flow-through was directed to waste. After the sample was loaded the affinity column was washed with 30% loading buffer (2 ml), followed by 100% loading buffer (5 ml) to reduce non-specifically bound components. A final wash

20 with water prepared the affinity column for elution (3 ml). The affinity column was now connected to the reversed-phase column (by valve switching) and eluted with elution buffer (2 ml) at a flow rate of 2 ml/min to transfer the affinity captured components to the reversed phase column. During this transfer step the Integral UV detector is located after the affinity column and before the reversed-phase column and hence monitors the elution of the affinity

25 column (which becomes the load to the reversed-phase column). In addition to this detector, a second detector was added after the reversed-phase column to monitor its flow-through to confirm that all the components eluted from the affinity column were in fact captured by the reversed-phase column.

Re-equilibration of the affinity column was subsequently performed with loading buffer

30 (4 ml) after removing its connection to the reversed-phase column.

The loaded reversed-phase column was washed with aqueous 0.1% TFA (2 ml). The flow rate was set to 1 ml/min and a rapid gradient (1 min) was run to 35% solvent 2B (0.1%

TFA/80% acetonitrile) followed by a shallow gradient to 50% solvent 2B over 14 min. Elution is completed by a gradient to 90% solvent 2B over 4 min. The reversed phase column was then returned to initial conditions over 1 min. and re-equilibrated for 3 min at 2 ml/min. The column eluate was monitored at 280 and 214 nm. Quantitation was performed by comparison 5 of the integrated peak areas with those of standards of known concentrations.

Fractions were collected across the gradient profile, pooled as appropriate and lyophilized. Peak fractions were partially characterized using the usual procedures employed in N-terminal sequence analysis, and SDS-PAGE analysis. They were also analyzed by liquid chromatography/mass spectrometry (LC/MS). N-terminal sequence analysis, LC/MS, and 10 SDS-PAGE revealed that Peak 5 on the chromatogram contained predominantly full-length antibodies in tetrameric form (i.e., two light chains and two heavy chains).

Production of full-length anti-TF antibodies using the polycistronic plasmid paTF20 (1-light, 1-heavy) or paTF40 (1-light, 3-heavy) was compared to that using the separate cistron vector paTF50 (1-light, 1-heavy), in the 43H1 *E. coli* strain. Fermentations have 15 also been conducted in 33D3 and 59A7 strains transformed with the paTF50 plasmid. Analysis of fermentation samples by the AME5-RP assay gave the following AME5-RP assay Peak 5 titers shown in Table 2:

**Table 2**

	<u>anti-TF Plasmid</u>	<u>E. coli</u> Host	<u>AME5-RP Peak 5 (mg/L)</u>
20	paTF20	43H1	13
	paTF40	43H1	18
	paTF50	43H1	134
	paTF50	33D3	115
	paTF50	59A7	156

25 Thus, as the AME5-RP results indicated, the separate cistron vector paTF50 produces significantly higher yields of intact anti-TF antibodies, compared to polycistronic vectors.

Fermentation products were purified as follows: bacteria cell paste was diluted 1:5 30 (w/v) in 20 mM sodium phosphate pH 7.4, 0.14 M NaCl, then lysed using an M110Y microfluidizer (Microfluidics Corp., Newton, MA). The solution containing lysed cells was clarified by centrifugation (4300xg, 30 min) to remove cellular debris. Polyethylene imine (BASF Corp., Rensselaer, NY) was added to the supernatant to a final concentration

of 0.2%, followed by centrifugation (4300xg, 30min). The supernatant was filtered (0.2  $\mu$ m) and applied to a Protein A affinity resin, Prosep A (Millipore Corp., Bedford, MA). The *E.coli* derived IgG<sub>1</sub> was eluted using 0.1 M acetic acid pH 2.9. The Protein A pool was conditioned by the addition of urea to a final concentration of 2M, adjusted to pH 5.5, 5 then diluted with purified water and applied to SP Sepharose FF (Amersham Pharmacia Biotech, Uppsala, Sweden). The SP Sepharose FF column was washed with 20 mM MES pH 5.5, followed by IgG<sub>1</sub> elution using a linear gradient from 0 to 0.25 M NaCl in 20 mM MES pH 5.5. SP Sepharose FF gradient fractions were analyzed by SDS-PAGE and pooled. The SP Sepharose FF pool was adjusted to pH 8.0 and applied to Q Sepharose FF 10 (Amersham Pharmacia Biotech, Uppsala, Sweden). The Q Sepharose FF column was washed with 25 mM Tris pH 8.0, 50 mM NaCl, followed by IgG<sub>1</sub> elution using 25 mM Tris pH 8.0, 150 mM NaCl. The Q Sepharose FF pool was formulated by ultrafiltration using a 10 kDa regenerated cellulose membrane (Millipore Corp., Bedford, MA), followed by diafiltration into 20 mM sodium acetate pH 5.5, 0.14 M NaCl.

15 **Example 5. Characterization of Full Length Antibodies Produced in *E. coli***

To further confirm that the full length antibodies produced in the *E. coli* host cells of the present invention possess desired properties, the anti-TF antibody products prepared by fermentation and purified according to the procedures of Example 4 were further characterized by a series of assays including Mass Spectrometry, Ion-Exchange 20 Chromatography, Size-Exclusion Chromatography, Amino Acid Analysis and N-terminal Sequencing.

**MALDI-TOF-MS Analysis:**

MALDI-TOF-MS was performed on a Voyager DE Biospectrometry WorkStation (Perseptive Biosystems, Framingham, MA) equipped with delayed extraction. A nitrogen 25 laser was used to irradiate samples with ultraviolet light (337 nm) and an average of 240 scans was taken. The instrument was operated in linear configuration (1.2 m flight path), and an acceleration voltage of 20 kV was used to propel ions down the flight tube after a 60 ns delay. Samples (1.0  $\mu$ l) were mixed with 1  $\mu$ l of matrix and 1  $\mu$ l of this mixture was added to the target and dried under vacuum (50 x 10<sup>-3</sup> Torr). Protein standards were used 30 to achieve a two point external calibration for mass assignment of ions.

4-Hydroxycinnamic acid matrix was used in the analysis of the full length anti-TF antibodies.

**Ion-Exchange Chromatography:**

Cation-exchange chromatography was carried out on a HP1100 instrument using Baker Bond CSX column (4.6x250mm). The column was equilibrated for 20 min with buffer A (25 mM sodium acetate, pH 4.8) at 1ml/min flow rate. The samples were diluted to 5 -approximately 1 mg/ml in buffer A and injected -approximately 50 ug. The column temperature was maintained at 40°C. A linear gradient was applied over 40 min to 60% buffer B (buffer A + 500 mM NaCl) and held at 60% buffer B for 5 min. The column effluent was monitored at 280 nm.

**Size Exclusion Chromatography:**

10 A TSK G3000SW-XL column (7.8 x 300 mM; TosoHaas) was used for size exclusion chromatography on a HP1100 instrument. The column was equilibrated with 100 mM potassium phosphate buffer pH 6.3 containing 250 mM sodium chloride at flow rate of 0.5 ml/min. Samples were diluted to 1 mg/ml with the elution buffer and 15 -approximately 100 ug was injected to the column. The run time was 30 min. Samples of gel filtration standards (Bio-Rad) were also injected after five-fold dilution with the elution buffer.

**Amino-Terminal Sequence Analysis:**

The sample was exchanged into 0.1% acetic acid by dialysis. An aliquot containing 83 ug was loaded for N-terminal sequence analysis by the Edman degradation method 20 using an Applied Biosystems 477A/120A automated protein sequencer. Peak height comparison to an external standard was used to quantitate PTH-amino acids.

**Amino Acid Analysis:**

Aliquots containing 15 ug of desalted samples were dried in hydrolysis ampoules by evaporation in a Savant SpeedVac. After addition of 6 N HCl (Pierce), the ampoules were 25 sealed under reduced pressure and incubated for 24 or 72 hours at 110°C. Additional aliquots were subjected to performic acid oxidation by incubation for four hours at 0-5°C with a solution prepared an hour earlier containing 10% hydrogen peroxide and 90% formic acid. The performic acid was subsequently removed by evaporation in a Savant SpeedVac, after which the samples were subjected to 24-hour hydrolysis in 6 N HCl as 30 described above. For Trp determinations, triplicate aliquots containing 25 ug of each lot were dried in ampoules and incubated at 110°C for 24 hours under a nitrogen atmosphere in

a 7% mercaptoacetic acid (Baker)/93% 6 N HCl (Pierce) solution under reduced pressure. After hydrolysis, all samples were dried by evaporation in a Savant SpeedVac.

Hydrolysates were reconstituted in a 0.2 N sodium citrate buffer, pH 2.2 (Beckman) and subjected to amino acid analysis using a Beckman 6300 cation exchange instrument  
5 with post-column ninhydrin detection. The signal representing the sum of the absorbance at 440 nm and 570 nm was monitored by a PE Nelson Turbochrom 4 data system. Amino acid quantitation was achieved by peak area or peak height comparisons to external standard mixtures containing 1 or 2 nmol of each component.

The results obtained from various assays described above confirmed that the full  
10 length anti-TF antibodies produced in *E. coli* using the expression vectors of the present invention share similar structural characteristics to those anti-TF antibodies produced in eukaryotic host cells, such as CHO cells.

#### **Example 6. Functional Analysis of the Full Length Antibodies Produced in *E. coli***

The antibodies produced and purified from *E. coli* according to the previous  
15 examples are full length and aglycosylated. The following experiments were performed to illustrate that the antibodies: 1) exhibit tight bivalent antigen binding ability; 2) lack C1q binding ability and therefore the CDC function is depleted; 3) lack Fc $\gamma$ R1 binding ability and therefore the ADCC functions are depleted; and 4) show strong FcRn binding, for improved resistance to clearance therefore promoting a longer half life *in vivo*.

#### **20 TF Antigen Binding**

The full length anti-TF antibodies were evaluated for antigen binding using an  
ELISA assay. MaxiSorp 96-well microwell plates (Nunc, Roskilde, Denmark) were coated  
with 1  $\mu$ g/ml soluble tissue factor (TF) comprising residues 1-219 (Genentech) in 50 mM  
carbonate buffer, pH 9.6, at 4°C overnight. Plates were blocked with PBS, 0.5% bovine  
25 serum albumin, 10 ppm Proclin 300 (Supelco, Bellefonte, PA), pH 7.2, at room  
temperature for 1 hour. Threefold serial dilutions of antibodies (0.27-200 ng/ml) in PBS,  
0.5% bovine serum albumin, 0.05% polysorbate 20, 0.25% CHAPS, 0.2% bovine  $\gamma$   
globulins (Sigma, St Louis, MO), pH 7.2 (assay buffer) were added to the plates and plates  
were incubated for 2 hours. Bound IgG was detected by adding peroxidase conjugated goat  
30 anti-human F(ab')2 antibody (Jackson ImmunoResearch, West Grove, PA) in assay buffer,  
incubating the plates for 1 hour and adding 3,3',5,5'-tetramethyl benzidine (Kirkegaard &

Perry Laboratories, Gaithersburg, MD) as the substrate. Plates were washed between steps with PBS, 0.05% polysorbate 20, pH 7.2. Absorbance was read at 450 nm on a Titerek stacker reader (ICN, Costa Mesa, CA). Titration curves were fitted using a four-parameter nonlinear regression curve-fitting program (KaleidaGraph, Synergy software, Reading, PA).

The results of the TF antigen binding ELISA assay are shown in Figure 15. The full length anti-TF antibodies made in *E. coli* (IgG1) are compared with anti-TF antibodies of different isotypes that were made in CHO cells. The *E. coli* made IgG1 antibody shows antigen binding activities that are at least comparable to the other anti-TF antibodies made in CHO cell systems.

### C1q Binding

The binding of human C1q to purified *E. coli* produced anti-TF antibody was determined using an ELISA binding assay as described in Idusogie et al. (2000) *J. Immuno* 164:4178-4184. Briefly, Costar 96 well plates were coated overnight at 4°C with various 15 concentrations of antibodies in coating buffer (0.05 M sodium carbonate buffer), pH 9. The plates were then washed 3x with PBS/ 0.05% TWEEN 20<sup>TM</sup>, pH 7.4 and blocked with 200µl of ELISA diluent without thimerosal (0.1M NaPO<sub>4</sub> / 0.1M NaCl / 0.1% gelatin / 0.05% TWEEN 20<sup>TM</sup>/ 0.05% ProClin300) for 1hr at room temperature. The plate was washed 3x with wash buffer, an aliquot of 100µl of 2 µg/ml C1q (Quidel, San Diego, CA) 20 was added to each well and incubated for 2 hrs at room temperature. The plate was then washed 6x with wash buffer. 100 µl of a 1:1000 dilution of sheep anti-human C1q peroxidase conjugated antibody (Biodesign) was added to each well and incubated for 1 hour at room temperature. The plate was again washed 6x with wash buffer and 100 µl of substrate buffer (PBS/0.012% H<sub>2</sub>O<sub>2</sub>) containing OPD (O-phenylenediamine dihydrochloride 25 (Sigma)) was added to each well. The oxidation reaction, observed by the appearance of a yellow color, was allowed to proceed for 30 minutes and stopped by the addition of 100 µl of 4.5 N H<sub>2</sub>SO<sub>4</sub>. The absorbance was then read at (492-405) nm using a microplate reader (SPECTRA MAX 250<sup>TM</sup>, Molecular Devices Corp.). The appropriate controls were run in parallel (*i.e.* the ELISA was performed without C1q for each concentration of the 30 antibodies used and also the ELISA was performed without the antibody). For each sample, C1q binding was measured by plotting the absorbance (492-405) nm versus concentration in µg/ml, using a 4-parameter curve fitting program (KALEIDAGRAPH<sup>TM</sup>)

and comparing EC<sub>50</sub> values. The results of this assay are depicted in Figure 16. A CHO cell-expressed antibody, I-1095-1-Rituximab, was used as a positive control. No C1q binding was detected from the *E. coli* made full length anti-TF antibody, even at high antibody concentrations.

### 5 Fc $\gamma$ Receptor Binding

The binding of Fc $\gamma$ R1 to purified anti-TF antibody was determined using the following ELISA binding assay. Fc $\gamma$ R1  $\alpha$  subunit-GST fusion was coated onto Nunc F96 maxisorb plates (cat. no. 439454) by adding 100 ul of receptor-GST fusion at 1 ug/ml in PBS and incubated for 48 hours at 4 $^{\circ}$ C. Prior to assay, plates were washed 3x with 250 ul of wash buffer (PBS pH 7.4 containing 0.5% TWEEN 20) and blocked with 250 ul of assay buffer (50 mM Tris buffered saline, 0.05% TWEEN 20, 0.5% RIA grade bovine albumin (Sigma A7888), and 2mM EDTA pH 7.4). Samples diluted to 10 ug/ml in 1 ml of assay buffer were added to Fc $\gamma$ R1  $\alpha$  subunit coated plates and incubated for 120 minutes at 25 $^{\circ}$ C on an orbital shaker. Plates were washed 5x with wash buffer to remove unbound complexes and IgG binding was detected by adding 100 ul horse radish peroxidase (HRP) conjugated goat anti-human IgG  $\gamma$  heavy chain specific (Boehringer Mannheim 1814249) at 1:10,000 in assay buffer and incubated for 90 min at 25 $^{\circ}$ C on an orbital shaker. Plates were washed 5x with wash buffer to remove unbound HRP goat anti-human IgG and bound anti-IgG was detected by adding 100 ul of substrate solution (0.4 mg/ml o-phenylenediamine dihydrochloride, Sigma P6912, 6 mM H<sub>2</sub>O<sub>2</sub> in PBS) and incubating for 8 min at 25 $^{\circ}$ C. Enzymatic reaction was stopped by the addition of 100 ul 4.5 N H<sub>2</sub>SO<sub>4</sub> and colorimetric product was measured at 490 nm on a 96 well plate densitometer (Molecular Devices). The results of this assay are depicted in Figure 17. The positive controls, mammalian 293 expressed antibodies, bind to the receptor but no Fc $\gamma$ R1 binding is detected for the *E. coli* produced anti-TF antibody.

### FcRn binding

The binding of purified anti-TF antibodies to FcRn was analyzed using the following ELISA binding assay. ELISA plates were coated with soluble tissue factor and blocked as described above. Two fold serial dilutions of anti-TF antibodies (1.6 - 200 ng/ml) in PBS, 0.5% bovine serum albumin, 0.05% polysorbate 20, pH 6.0 (sample buffer) were added to the plates and plates were incubated for two hours at room temperature. Biotinylated FcRn (prepared using biotin-X-NHS from Research Organics, Cleveland, OH)

at 3.6  $\mu$ g/ml in sample buffer was added to the plates. After a 1 hour incubation, bound FcRn was detected by adding streptavidin labeled peroxidase (Amplex, Copenhagen, Denmark) in sample buffer, incubating the plates for 1 hour and adding 3,3',5,5'-tetramethyl benzidine (Kirkegaard & Perry Laboratories) as the substrate. Plates were 5 washed between steps with PBS, 0.5% BSA, 0.05% polysorbate 20, pH 6.0. Absorbance was read at 450 nm on a Thermo<sub>max</sub> plate reader (Molecular Devices, Menlo Park, CA). Titration curves were fit as described above. Figure 18 shows that the FcRn binding activity of the *E. coli* made full length anti-TF antibody is comparable to other anti-TF antibodies (IgG4, IgG4b, IgG2) made in mammalian host cells.

10 **Example 7. Pharmacokinetics Study of the Full Length  $\alpha$ -TF Antibodies Made in *E. coli***

The *E. coli* made full length anti-TF antibody (IgG1 *E. coli*) was subject to a single IV bolus dose chimpanzee pharmacokinetic (PK) study, along with two other anti-TF antibodies made in CHO cells (IgG2 CHO and IgG4b CHO) as controls. Three 15 chimpanzees were tested negative for the presence of anti-TF antibodies. Each animal received a single IV bolus dose of anti-TF antibody (IgG1 *E. coli*, IgG2 CHO or IgG4 CHO) at 0.10 mg/kg. Plasma samples were collected up to 28 days post dosing according to the following schedule: 30 and 15 minutes predose; 2, 15, 30 minutes; 1, 2, 3, 4, 6, 12 hours; 1, 2, 4, 7, 14, 21, and 28 days post IV bolus dose. Plasma samples were assayed for 20 anti-TF antibody (ATF) content by ELISA, using TF as a coat and an anti-Fc monoclonal antibody as a detecting antibody. The limit of quantification was 0.102  $\mu$ g/ml in chimpanzee plasma.

The ELISA results is shown in Figure 19 in the form of plasma ATF concentration versus time curves. The data were fit to a one-compartment elimination profile in Win 25 Nonlin 3.0. The PK parameter estimates of Clearance (CL), elimination half-life ( $T_{1/2}$ ) and Volume (V) are reported in Table 3. Based on this experiment in three individual chimpanzees, no obvious differences in PK parameter estimates were observed between the antibody made in *E. coli* and those made in CHO cells.

**Table 3**

Chimp Number	202	336	569
Antibody	IgG1 <i>E. coli</i>	IgG4b CHO	IgG2 CHO

CL (ml/day/kg)	36.3	44.6	91.8
T <sub>1/2</sub> (day)	0.938	0.926	0.694
V (ml/kg)	49.2	59.6	92.0

**Example 8. Expression and Fermentation of Various Full Length Antibodies using Separate Cistron Vectors**

Separate cistron vectors were also constructed for the expression of the following 5 full length antibodies: anti-VEGF (VNERK), a higher affinity variant of the humanized antibody described in Presta et al., *Cancer Res.* 57:4593-4599 (1997); a humanized anti-IgE antibody described in Presta et al., *J. Immunol.* 151:2623-2632 (1993); anti-CD40, a humanized version of the anti-CD40 antibody described in Francisco et al., *Cancer Res.* 60:3225-3231 (2000); anti-HER-2 (versions 4D5 and 2C4; Carter et al., *Proc. Natl. Acad. Sci. USA* 89:4285-4289 (1992) and Fendly et al., *Cancer Res.* 50:1550-1558 (1990); and a 10 humanized anti-CD18 (Eigenbrot et al., *Proteins: Structure, Function, and Genetics* 18:49-62 (1994)).

For the construction of separate cistron plasmids, the V<sub>L</sub> and V<sub>H</sub> regions of paTF50 (TIR1-light, TIR1-heavy; see Example 1) were replaced with the V<sub>L</sub> and V<sub>H</sub> of each of the 15 listed antibodies. Expression induction was carried out in strain 33D3, as described in Example 3. Samples were removed for SDS-PAGE separation and immunoblot under non-reducing conditions. As shown in Figure 22, full length versions of antibodies anti-VEGF, anti-IgE, anti-CD40, 4D5, 2C4 and anti-CD18 were successfully expressed in *E. coli* using 20 separate cistron vectors. This data illustrates that the separate cistron expression system is a generally applicable approach for antibody expression in *E. coli*.

To further illustrate the utility of the separate cistron expression system described herein, the above-described plasmids expressing various listed antibodies were used in large-scale productions (fermentation processes).

The organisms used for these fermentations include: 33D3 W3110 ΔfhuA (ΔtonA) 25 ptr3 lac Iq lacL8 ΔompTΔ(nmpc-fepE) degP41 kan<sup>R</sup>; 61D6 W3110 ΔfhuA (ΔtonA) ptr3 lac Iq lacL8 ΔompTΔ(nmpc-fepE) degP41; and 62A7 W3110 ΔfhuA (ΔtonA) ptr3 lac Iq lacL8 ΔompTΔ(nmpc-fepE) degP41 ilvG repaired.

Fermentations of the listed antibodies were done at the 10-liter scale and soluble samples prepared and submitted to the AME5-RP assay as described in Example 4. The AME5-RP assay titers of peak 5 containing full length antibodies predominantly in tetrameric form (two L chains and two H chains), are shown in Table 4.

5 **Table 4**

<b>Antibody</b>	<b>E. coli host</b>	<b>AME5-RP Peak 5, mg/L</b>
anti-TF	61D6	112
anti-CD18	61D6	34
anti-IgE (E25 variant)	33D3	77
10 anti-VEGF (VNERK variant)	61D6	53
anti-CD40	62A7	45
anti-Her2 (4D5 variant)	62A7	55
anti-Her2 (2C4 variant)	62A7	73

15

**Example 9. Co-expression of Dsb proteins and Full Length Antibodies in *E. coli***

Using the separate cistron system of the invention, full length anti-TF antibodies were also co-expressed with one or more Dsb proteins that are capable of facilitating the proper folding and assembly of the antibodies.

20

The organisms used for these fermentations include: 58H7 W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $\Delta ptr3$   $\Delta ompT$   $\Delta degP$  *lac Iq*  $\Delta lacY$ ; and 61D6 W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $ptr3$  *lac Iq lacL8*  $\Delta ompT$   $\Delta (nmpc-fepE)$  *degP41*.

25

anti-TF encoding plasmid paTF50 or pxTF2AP22 (a paTF50 variant with TIRs of 2 for both light chain and heavy chain) was used to transform competent cells of the above organisms. Plasmids encoding either dsbC (pJJ141), dsbA (pJJ142), or dsbA/C (pJJ247) were co-transformed with the anti-TF plasmid paTF50 or pxTF2AP22.

30

To construct the dsbC plasmid pJJ141, the kanamycin resistant plasmid pACYC177 was digested with AatII and HincII disrupting ampicillin resistance. The tac-dsbC plasmid pJJ40, described in US Patent No. 5,639,635, was digested with ClaI and then filled in with Klenow and deoxynucleotides. After phenol:chloroform extraction and precipitation, the linearized vector was digested with AatII and the 1.6 kb fragment was purified from an agarose gel and ligated to AatII/HincII digested pACYC177. The final plasmid pJJ141

encodes tac-dsbC and confers kanamycin resistance. Similarly, the dsbA plasmid pJJ142 was constructed using the same AatII/HincII cut parent vector ligated with a AatII/ClaI (filled in ClaI site) fragment from pJJ37, which encodes dsbA and is also described in US Patent No. 5,639,635.

5 To construct pJJ247, the plasmid encoding both dsbA and dsbC, pJJ142 was digested with KpnI and ScaI. DsbC was PCR amplified from plasmid pJJ141 using the following primers:

tacdsbCf1: CATAACTGGTACCCAGGATCTAGAGGGAAAGATTATG (SEQ ID NO:3)

tacdsbCr2: CTGGTGAGTACTCAACCAAGTCATTCTG (SEQ ID NO:4)

10 The primers contain restriction sites (KpnI, ScaI) which are underlined. After PCR amplification, the fragment was purified by agarose gel electrophoresis and digested with the appropriate enzymes and ligated to KpnI/ScaI digested pJJ142. The resulting plasmid, pJJ247, encodes a tac promoter driving the expression of both dsbA and dsbC with dsbA first in the series. The plasmid was sequenced from the middle of the dsbA gene through 15 the 3' end of the dsbC gene.

In some cases, single plasmids encoding both anti-TF with a TIR of 1 for both light chain and heavy chain and either DsbC (pJJ241) or DsbA (pJJ237) were constructed to transform competent host cells.

20 To construct the plasmid pJJ237 which co-expresses anti-TF and dsbA, the anti-TF plasmid pATF50 was digested with AatII and HpaI and ligated to a AatII/HpaI cut fragment from pJJ223. This latter fragment contains araC, the pBAD promoter, dsbA, kanamycin resistance, a colE1 origin of replication, and the  $\beta$ -lactamase gene. The product of the ligation contains: both L and H chains of anti-TF under separate phoA promoters, an arabinose inducible promoter (pBAD) driving expression of dsbA with the plasmid 25 conferring kanamycin and ampicillin resistance. This plasmid was termed pJG9. To make pJJ237, the arabinose regulon was changed to the tac promoter by PCR amplification. To do this, the following primers were used:

dsbAf11: TGCACGGTTAACATGCTGTGGTGTCAGGTCGG (SEQ ID NO:5)

dsbAr12: TTTACCGTTAACAAACATGCCGGAAC (SEQ ID NO:6)

30 The underlined sites are HpaI sites. After amplification using pJJ142 as the template (contains tac-dsbA), the fragment was gel purified and digested with HpaI. The

pJG9 vector was digested with HpaI and NaeI removing the araC-pBAD-dsbA region. The HpaI-NaeI cut vector was gel purified and ligated to the tac-dsbA HpaI cut PCR fragment. The resulting plasmid, termed pJJ237, contains the separate phoA promoters driving expression of  $\alpha$ TF L and H chains and the tac promoter driving dsbA expression.

5 To construct plasmid pJJ241 which co-expresses anti-TF and dsbC, pJG9 was digested with HpaI and NgoMIV. NgoMIV cuts at the same site as NaeI but leaves a sticky end instead. DsbC was PCR amplified from pJJ141 as the template with the same forward primer as dsbA (dsbAf11; SEQ ID NO:5) and the reverse primer as follows:

dsbCr12: TCAGCTGCCGGCGTCCGATGCGAATTTTTACCG (SEQ ID NO:7)

10 The underlined site is a NgoMIV site. The amplified fragment was gel purified and digested with NgoMIV and HpaI and ligated to pJG9. The resulting plasmid contains the separate phoA promoters driving expression of anti-TF L and H chains and the tac promoter driving dsbC expression.

15 When a plasmid encoding anti-TF and a plasmid encoding one or more Dsb proteins were used together to transform the competent cells, transformants were plated on LB agar plates containing 50  $\mu$ g/mL of both carbenicillin and kanamycin. In those cases where a single plasmid expressing both anti-TF and the selected Dsb proteins (dsbA or dsbC), transformants were selected on LB agar plates containing 50  $\mu$ g/mL of kanamycin.

20 Fermentations were done at the 10-liter scale as described in Example 4, with the addition of 50 mL of a 200 mM solution of isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) to the fermentation culture when the OD<sub>550</sub> reached 150-200. IPTG additions can be made at times other than the one described and different amounts of IPTG than described can be also added. Soluble samples were prepared and submitted to the AMES-RP assay as described in Example 4. The various plasmid/host strains and resulting titers of peak 5 are 25 summarized in Table 5.

**Table 5**

<u>anti-TF Plasmid</u>	<u>E. coli</u> Host	Dsb Plasmid	AMES-RP Peak 5 (mg/L)
paTF50	58H7	none	100
paTF50	61D6	none	127
30 paTF50	58H7	pJJ141	174
pJJ241	58H7	pJJ241	212

	paTF50	58H7	pJJ142	125
	pJJ237	58H7	pJJ237	135
	paTF50	61D6	pJJ247	584
	pxTF2AP22	61D6	none	118
5	pxTF2AP22	58H7	pJJ141	349
	pxTF2AP22	58H7	pJJ142	134
	pxTF2AP22	61D6	pJJ247	881

**Example 10. Co-expression of FkpA and Full Length Antibodies in *E. coli***

10 Full length anti-TF antibodies were also co-expressed with FkpA, a peptidylprolyl cis,trans-isomerase with chaperone activity.

The organisms used for these fermentations include: 58H7 (genotype W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $\Delta ptr\beta$   $\Delta ompT$   $\Delta degP$   $lac$   $Iq$   $\Delta lacY$ ); and 59A7 (genotype W3110  $\Delta fhuA$  ( $\Delta tonA$ )  $phoA\Delta E15$   $\Delta (argF-lac)169$   $deoC$   $degP41$   $kan^S$   $ilvG^+$   $\Delta prc::kanR$   $prc$  suppressor).

15 A separate plasmid encoding fkpA under the control of the tacII promoter (pJVG2) was co-transformed with anti-TF plasmid paTF50. To create pJVG2, plasmid pJJ222fkpA was digested with NheI and NgoMIV to create a 0.8 kb fragment containing fkpA. This fragment was purified by electrophoresis and phenol:chloroform extraction and precipitation. Plasmid pJJ239 which contains tac-DsbD on a pACYC177 vector analogous to pJJ142, was digested with XbaI and NgoMIV to create a 3.9 kb fragment containing an inducible tac promoter and kanamycin resistance. This fragment was purified by electrophoresis and phenol:chloroform extraction and precipitation. These two fragments were ligated creating pJVG2 containing an inducible tac promoter, fkpA and kanamycin resistance. This plasmid is similar to pJJ141 and pJJ142 in that it's a compatible 20 pACYC177 plasmid that can be used to co-express fkpA with pBR322 based plasmids.

25 In addition, a single plasmid encoding both anti-TF chains under the control of separate phoA promoters and fkpA under the control of the arabinose promoter (pJG9fkpAB3) was used to transform competent cells of the above organisms. To create pJG9fkpAB3, plasmid pJJ222fkpA was digested with HpaI and NdeI to create a 4.1 kb fragment containing araC, the inducible promoter pBAD, fkpA and kanamycin resistance. FkpA had been originally PCR amplified from the *E. coli* chromosome and cloned behind the pBAD promoter in commercially available pBAD18. The fragment was purified by 30

electrophoresis and phenol:chloroform extraction and precipitation. Plasmid pJG9 was digested with HpaI and NdeI to create a 5.1 kb fragment containing ampicillin resistance, the separate cistrons for both L and H chains of  $\alpha$ TF antibody. It was purified by electrophoresis and phenol:chloroform extraction and precipitation. The two fragments 5 were ligated to create pJG9fkpAB3, which contains separate promoters driving expression of anti-TF antibody chains, araC, the pBAD promoter driving expression of only fkpA, kanamycin resistance, a colE1 origin of replication, and ampicillin resistance.

When the anti-Tissue Factor plasmid paTF50 and the fkpA plasmid pJVG2 were used together to transform the competent cells, transformants were plated on LB agar plates 10 containing 50  $\mu$ g/mL of both carbenicillin and kanamycin. When cells were transformed with the single plasmid pJG9fkpAB3, transformants were selected on LB agar plates containing 50  $\mu$ g/mL of kanamycin.

Fermentations were done at the 10-liter scale as described in Example 4 with the following modifications. Fermentations using the cells transformed with the plasmid 15 pJG9fkpAB3 had an addition of 200 mL of a 40% arabinose solution at approximately an OD550 of 150-200. Prior to the arabinose addition, the glucose feed rate was cut such that the culture became glucose limited. After the arabinose addition and consumption, the glucose feed rate was resumed to allow maximum glucose uptake by the culture. Fermentations using the cells co-transformed with the plasmids paTF50 and pJVG2 had an 20 addition of 50 mL of a 200 mM solution of isopropyl  $\beta$ -D-thiogalactopyranoside (IPTG) to the fermentation culture when the OD550 reached 150-200. IPTG additions can be made at times other than the one described and different amounts of IPTG than described can be also added. Soluble samples were prepared and submitted to the AME5-RP assay as described in Example 4.

25 The fermentation with the 59A7 host transformed with paTF50 gave an AME5-RP Peak 5 titer of approximately 156 mg/L, compared to 247 mg/L for the 59A7 host transformed with the pJG9fkpAB3 plasmid. Likewise, the fermentation with the 58H7 host transformed with the plasmid paTF50 gave an AME5-RP Peak 5 titer of approximately 100 mg/L compared to 180 mg/L for the 58H7 host co-transformed with 30 paTF50 and pJVG2.

Although the forgoing refers to particular embodiments, it will be understood that the present invention is not so limited. It will occur to those ordinary skilled in the art that various modifications may be made to the disclosed embodiments without diverting from the overall concept of the invention. All such modifications are intended to be within the 5 scope of the present invention.

What is claimed is:

1. A polynucleotide molecule encoding an immunoglobulin, said polynucleotide molecule comprising (1) a first promoter and a first cistron forming a first promoter-cistron pair and (2) a second promoter and a second cistron forming a second promoter-cistron pair, wherein the first cistron of said first promoter-cistron pair comprises a first translational initiation region (TIR-L) operably linked to a nucleic acid sequence encoding an immunoglobulin light chain and the second cistron of said second promoter-cistron pair comprises a second translational initiation region (TIR-H) operably linked to a nucleic acid sequence encoding an immunoglobulin heavy chain, wherein upon expression of said polynucleotide in a prokaryotic host cell, the light and heavy chains are folded and assembled to form a biologically active immunoglobulin.  
5
2. The polynucleotide molecule of claim 1, wherein the first and second promoters are prokaryotic promoters selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, trp, trc and T7 promoters.  
10
- 15 3. The polynucleotide molecule of claim 2, wherein both promoters are PhoA promoters.
4. The polynucleotide molecule of claim 1, wherein each of the TIR-L and TIR-H comprises a prokaryotic secretion signal sequence or variant thereof.  
15
5. The polynucleotide molecule of claim 4, wherein the prokaryotic secretion signal sequence is selected from the group consisting of STII, OmpA, PhoE, LamB, MBP and PhoA secretion signal sequences.  
20
6. The polynucleotide molecule of claim 1, wherein the TIR-L and TIR-H provide approximately equal translational strengths.  
25
7. The polynucleotide molecule of claim 6, wherein the relative translational strength combination is about (1-TIR-L, 1-TIR-H).  
25
8. A recombinant vector for expressing an immunoglobulin in a prokaryotic host cell, said vector comprising the polynucleotide molecule of claim 1.  
25
9. A prokaryotic host cell comprising the recombinant vector of claim 8.

10. The prokaryotic host cell of claim 9 which is a gram-negative bacterial cell.
11. The host cell of claim 10 which is *E. coli*.
12. The host cell of claim 11, further comprising a polynucleotide encoding at least one prokaryotic polypeptide selected from the group consisting of DsbA, DsbC, DsbG and
- 5 FkpA.
13. The host cell of claim 12, wherein the polynucleotide encodes both DsbA and DsbC.
14. The host cell of claim 11, wherein the *E. coli* is of a strain deficient in endogenous protease activities.
- 10 15. The host cell of claim 14, wherein the genotype of the *E. coli* strain lacks *degP* and *prc* genes and harbors a mutant *spr* gene.
16. A process for producing a biologically active immunoglobulin in a prokaryotic host cell, said process comprising expressing in the host cell a polynucleotide comprising (1) a first promoter and a first cistron forming a first promoter-cistron pair and (2) a second promoter and a second cistron forming a second promoter-cistron pair, wherein the first cistron of said first promoter-cistron pair comprises a first translational initiation region (TIR-L) operably linked to a nucleic acid sequence encoding an immunoglobulin light chain and the second cistron of said second promoter-cistron pair comprises a second translational initiation region (TIR-H) operably linked to a nucleic acid sequence encoding
- 15 20 an immunoglobulin heavy chain, wherein upon expression of said polynucleotide, said light chain and heavy chain are folded and assembled to form a biologically active immunoglobulin; and recovering said immunoglobulin.
17. The process of claim 16, wherein the first and the second promoters are prokaryotic promoters selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, trp, trc and
- 25 T7 promoters.
18. The process of claim 17, wherein both the first and the second promoters are PhoA promoters.

19. The process of claim 16, wherein each of the TIR-L and TIR-H comprises a prokaryotic secretion signal sequence or variant thereof.
20. The process of claim 19, wherein the prokaryotic secretion signal sequence is selected from the group consisting of STII, OmpA, PhoE, LamB, MBP and PhoA secretion signal sequences.  
5
21. The process of claim 16, wherein the TIR-L and TIR-H provide approximately equal translational strengths.
22. The process of claim 21, wherein the relative translational strength combination is about (1-TIR-L, 1-TIR-H).
- 10 23. The process of claim 16, wherein the prokaryotic host cell is *E. coli*.
24. The process of claim 16, further comprising expressing in the prokaryotic host cell a polynucleotide encoding at least one prokaryotic polypeptide selected from the group consisting of DsbA, DsbC, DsbG and FkpA.
25. The process of claim 24, wherein the polynucleotide encodes both DsbA and DsbC.  
15 26. The process of claim 23, wherein the *E. coli* is of a strain deficient in endogenous protease activities.
27. The process of claim 26, wherein the genotype of the *E. coli* lacks *degP* and *prc* genes and harbors a mutant *spr* gene.
28. An aglycosylated full length antibody produced by a process according to claim 16.  
20 29. The aglycosylated full length antibody of claim 28, wherein the immunoglobulin is a multispecific antibody.
30. The aglycosylated full length antibody of claim 28, which is a non-human antibody.
31. The aglycosylated full length antibody of claim 30, wherein the non-human antibody is humanized.
- 25 32. The aglycosylated full length antibody of claim 28, which is a human antibody.

33. An immunoconjugate comprising the aglycosylated full length antibody of claim 28 conjugated with a cytotoxic agent.
34. The immunoconjugate of claim 33, wherein the cytotoxic agent is selected from the group consisting of a radioactive isotope, a chemotherapeutic agent and a toxin.
- 5 35. The immunoconjugate of claim 34, wherein the toxin is selected from the group consisting of calichemicin, maytansine and trichothene.
36. A composition comprising the aglycosylated full length antibody of claim 28 and a carrier.
37. The composition of claim 36, wherein the carrier is pharmaceutically acceptable.
- 10 38. A composition comprising the immunoconjugate of claim 33 and a carrier.
39. The composition of claim 38, wherein the carrier is pharmaceutically acceptable.
40. An article of manufacture comprising a) a container and a composition contained therein, wherein the composition comprises an aglycosylated full length antibody of claim 28; and b) instruction for using said composition.
- 15 41. An article of manufacture comprising a) a container and a composition contained therein, wherein the composition comprises an immunoconjugate according to claim 33; and b) instruction for using said composition.



Fab Expression Vector pAK19Full Length Antibody Expression Vector Derived from pAK19

Figure 1

2/26




Figure 2

## Polycistronic Constructs




Figure 3.

4/26





Figure 4



Light Chain ConstructionsHeavy Chain Constructions

Figure 5




Figure 6

7/26




Figure 7

8/26




Figure 8

9/26

## Separate Cistron Constructs




Figure 9

10/26





Figure 10



- 1) negative control
- 2) TIR 1-light, TIR 1-heavy, polycistronic
- 3) TIR 3-light, TIR 1-heavy, polycistronic
- 4) TIR 1-light, TIR 3-heavy, polycistronic
- 5) TIR 1-light, TIR 1-heavy, separate cistrons
- 6) TIR 1-light, TIR 3-heavy, separate cistrons
- 7) TIR 3-light, TIR 1-heavy, separate cistrons
- 8) TIR 3-light, TIR 3-heavy, separate cistrons

Figure 11




Figure 12

13/26




Figure 13

14/26




Figure 14




Figure 15

16/26




Figure 16

17/26




Figure 17

18/26




Figure 18




Figure 19

1 GAATTCACT TCTCCATACT TTGATAAAG AAATACAGAC ATGAAATTC TCATGCTGA GTGTTATT AAAGTGGCC AAAGAAGAAGA AGAGTCGAAT  
CTTATGTTGA AGAGGTAGA AACCTTTCCTC TTATGCTG TACITTTAG AGTAAGACT CAACAAATAA TTGCAAGGSS TTTTCTCTCT TCTCAGCTTA  
101 GAACTGTGCG CGAGGTAGA AGCTTGGG ATTATCTCA CTGCAATGT TCGCAATATG GCGCAAAATG ACCAACAGCG GTTGTGAT CAGTAGGG  
CTTGACACAC GCCTCCATCTC TGAAACCTC AGCGTTATAC CGCTTTCATC TGGTGTGCG CAACAAATAA GTCCATCTCC  
201 GGGCGCTGTA CGAGGTAAAG CCCGATGCCA GCATTCCTGA CGACCATAGC GAGCTGCTGC GCGATTAGT AAAGAGTT TGAAGCATC CTCGCTGTA  
CCCGGACAT GCTCCATTC GGGTACGGT CGTAAAGCT GCTGCTATGC CTGACGAGC GCTPAATGCA TTTCCTCAT AACTCTGPG GAGCAGTCAT  
301 AAAAGTAAAT CTTTCAACA GCTGCTATAA AGTGTGCTCG GCGGAGACTT ATAGTCGCTT TGTTTTATTT TTGTTACTA GTAGCGAGT  
TTTTCATTA GAAAAGTTG CGAGCTATT TCAACAGTC CGGCTCTGAA TATCGGGAA ACACAAATAA AAATTCATAT AAACATGAT CAGCGCTCA  
401 TCACGTAATAA AGGTATCTA GAAAGATACT GCATTCCTC TTGCAATCT AGTGTGCTT TTGTTCTTTT TTGTTACTA GTAGCGAGT CGCTGATATC  
AGTGCATTTC TCCCATAGT CTTAAATCTT CTCTCTTAAAGG AACTGAGAAG AACTGAGAAG AACTGAGAAG AACTGAGAAG AACTGAGAAG  
501 CAGATGACC AGTCGCCAG CTCCCCTGCC GCCTCTGCG CCGTATGGT CACCATACCC TGCAGGGCCA GTCCGAGCTT CAAGAGCTAT CTGAGCTGTT  
GTCCTACGGG TGAGGGCTC GAGGGACGG CGGAGACACC CGCTATCCA GTGGTGTGCG AGTGTGCTGTT CAGGCTCTA GTTCCTGATA GACTGACCA  
591 ATCACACAGA ACCAGGAAA GCTCCGAAG TACTGATTTA CTATGCTACT AGTCTGCGNG AAGGAGTCCC TTCTGCGTC TCTGGATCCG GTTCCTGGGC  
TAGTGTGCTT TAGTGTGCTT CGAGCTTCTT ATGACTAAT GATAGCTGA TCAGACGAC TCTCTCAGGG AAGACGGAG AGACATGGC CAAGACCCCTG  
60 Q K P G K A P K V L I Y Y A T S L A B G V P S R F S G S G S G T  
1 STII signal sequence TIR-1  
60 Q K P G K A P K V L I Y Y A T S L A B G V P S R F S G S G S G T  
60 Q Q M T Q S P S S L S A S V G D R V T I T C R A S R D I K S Y L N W Y  
701 GGATTCACT CTGACCCATCA GCAGCTGCG GCTCAGGACTT ATTACTGCTT TCAGCACCGA GAGTCCTCAT GGACATTTGG ACAGGGTACG  
CCTTATGTTGA GACTGGTGTG AGTGTGCTT CCTGCAAGCTT CGGTCCTCTG AAGGTTGTA TAATGCGACA AGTGTGCTG CTGAGGAGC CCTGAAACCC  
93 D Y T L T I S S L Q P E D F A T Y Y C L Q H G E S P W T F G Q G T  
801 TGAATTAACCT CTATCCGAA TGTGCTGCA CCTATCTCTCT TCAATCTCCC GGCTCTGAT GAGGAGTGA ATATCGTAC TGCTCTGTT GTGTGCTGC  
TTCCACCTCT AGTGTGCTG ACACGGAGT GTGAGCTGAGA AGTGAAGGG CGGTGACTA CTGCTCAACT TTGAGGAGT GTCAAGAGTC AGGACAGCAA  
901 TGAATTAACCT CTATCCGAA GAGGGCAAG TACAGCTGAA GGTGGGATAAC GCCTCTCAT CGGTAACTC CGGGAGGTTA GCCCTTGTGAG  
ACTTATGAA GATAGGCTT CTCCGGTTT ATGTCACCTT CCACCTATTG CGGGAGGTTA Q E S V T E Q D S K  
160 N N F Y P R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K  
1001 CGACAGGACC TACACCCCA CGAGGACCT GAGCTGAGC AAAGCAAGCT ACAGGAACAA CAAGCTCAGC GCTGGCGAG TCACCCATCA GGCCCTGAGC  
CCGGTCTGG ATGTCGGTGT CCTCGTGGGA CTGCTGATCG TTTCGCTGTA TGCTCTTGT GTTCCTGATG CGACGCTTC AGTGGTGTG CTGGGACTCG  
191 D S T Y S L S S T L T L S K A D Y E K H K V Y A C E V T H Q G L S  
1101 TCGCCCGTCA CAAGAGCTT CAAGGGGA GAGCTCTAT TAATCTCTCT ACGGGGAGG CATGGGGCG AGCTGGGTAC CGGGGGATCT AGGCTTAACG  
ACGGGGGACT GTTCTGGA GTTGTCCCTT CTCAGATTA ATTAGGAGA TCGCCCTAGA TCGGCCATG GGCCCTAGA TCGGGATTC  
226 S P V T K S F N R G E C O

Figure 20a

1201 CTGGTGTGGC GCGGGGGT TTTTATTGTT GCGGAGGGC ATCTGAGTAA AACCTGGTGC CGTACAGC TTGAGTAC TGGATCTT CGAACATCTT AATTCAGCA  
 GAGCCACGG CGGCCCCAA AAATTAACAA CGGGCGGG TAGATCTAC TTGAGTAC CGTACAGC CGTACAGC TTGAGTAC TGGATCTT CGAACATCTT AATTCAGCA  
 1301 CGAAATATGG CGCAAAATGCA CGAACAGGG TGGATGATC AGTAGAGG GGGCGGTAC GAGGTAAAGC CGTACAGC TTGAGTAC TGGATCTT CGAACATCTT  
 GCGTTATACCG CGGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT GGTGTTACT  
 1401 AGCTGGGGG CGATTAGTA AAGAGTTAT TGAAGCTATG CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC TTGAGTAC GGGAGCTTA  
 TCGAGGAGGC AGTTAGCT ATCTGAGTAA AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC TTGAGTAC GGGAGCTTA  
 1501 TAGTCGCTT GTTGTATT TTTATGTT TTTATGTT TTTATGTT AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC TTGAGTAC  
 ATCAGGAA AAATTAACAA AAATTAACAA AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC  
 1 ST11 signal sequence TIR-1  
 10 A S M F V F S I A T N A Y A E V Q L V E S C G G L V Q P G G S L R  
 11 Anti-Tissue Factor Heavy Chain  
 1601 TGGATCTATG TGGTTTATG TTTATGTT AACAGGGTAC GGTGGGGTAC AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC  
 AGCTGAGTAC AGGAAAAA GATAGAGT TTGGCGATG CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC CGTACAGC  
 1701 TGTCTCTG CAGCTCTGG CTTCATATT AACGGTACT ACATGAGTAC GGTGGGGTAC AACCTGGTGC CGTACAGC TTGAGTAC AACCTGGTGC  
 ACAGGAGAC GTGAGAAC GAGGTTATTA TTGGCTATAC CGAGCTAC TTGGCTATAC CGAGCTAC TTGGCTATAC CGAGCTAC TTGGCTATAC  
 43 L S C A N S G F N I K E Y Y M H W V R Q A P G K G L E H V G L I D P  
 1801 CGAGGAGG CAGACGATC TATGGACCA AGTTCAGGA CGTGTGACT ATTAACGGTCA AGTACGCTCA AAACACGCA AACACAGCA ATGAGCTCT  
 GTCCTTCG GTGAGCTG ATATGGCTT TCAGGCTCT CGAGCTGCTT CGAGCTGCTT CGAGCTGCTT CGAGCTGCTT CGAGCTGCTT  
 77 E Q G N T I Y D P K F Q D R A T I S A D N S K N T A Y L Q M N S L  
 1901 GCGCTGGAG GAGCTGGCC TCTTATTG TGGCTGGAG ACCTGGTCA CGTGGGGTCA CGGCGCTTG AGTGGGGTCA CGGCGCTTG AGTGGGGTCA  
 CGGCGCTTG CGAGCTGGCC TCTTGGGGTCA CGGCGCTTG AGTGGGGTCA CGGCGCTTG AGTGGGGTCA CGGCGCTTG AGTGGGGTCA CGGCGCTTG  
 110 R A E D T A V Y Y C A R D T A Y F D Y W G Q G T L V T V S S A S  
 2001 ACCAGGGCC CGAGGGCTT CGGGCTGGCA CGGGGGGGG GGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG  
 TGGTCCCGG GTAGCCAGGA GGGGGGGG GGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG  
 143 T K G P S V F P L A P S S K S T S G G T A A L G K D Y F P E P  
 2101 CGGGAGGGT GTGGGGAAC TGGGGGGAC TGGGGGGAC TGGGGGGAC TGGGGGGAC TGGGGGGAC TGGGGGGAC TGGGGGGAC  
 GGGGGGGG  
 177 V T V S W N S G A L T S G V H T F P A V L Q S S G L Y S L S S V V  
 2201 GACTGTGCCC TTAGGAGCT TGGGGGGCA GGGGGGGG GGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG  
 CGAGGAGGG AGATGGTGA ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG ACCGGGGTCTTGGGGGGG  
 210 T V P S S L G T Q T Y I C N V N H K P S N T K V D K K V E P K S  
 2301 TGTGACAAA CGGCGGGG  
 AGCTGGTGTAC GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG GGTGGGGGG  
 243 C D K T H T C P P C P A P E L L G G P S V F L F P P K P K D T L M I  
 2401 TCTCCCGGAC CGCTGGGGTAC AACCTGGTGC CGTGGGGGGG CGGGGGGGG GGGGGGGG GGGGGGGG GGGGGGGG GGGGGGGG GGGGGGGG  
 AGAGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG GGGGGGGGG  
 277 S R T P E V T C V V V D V S H E D P E V K F N W Y V D G V E V H N

Figure 20b

2501 TGCCAAAGACA AAGGGAGGG AGGAGGAGTA CAACAGACG TACCGGTGAG TCAGGGTCTG CACCGGTCTG CACCGGTACTG CAAGGGAGTGG CAAGGGAGTAC  
 ACGGTTCTGT TTGGGGCCC TCTTCATAT GTTGTCTGCTG ATGGAAACCC AGTGGAGGA GTGGGGAGAC GTGGCTCTGA CGGACTTACCG GTTCCTCTGC  
 310 A K T K P R E Q Y N S T Y R V V S V L T V L H Q D W L N G K E Y  
 2601 AAGTGCAGG TCTCCACAA AGCCCTCCA AGAAACAT CTCCAAAGCC AAAGGGAGGC CGGGAAACC AGAGGTCTAC ACCCTGCCCC  
 TTACAGTTC AGAGGTGTT TCGGGAGGT CGGGGTAGC TCTTCTGTA GAGGTCTGG TTTCCTGCG GGGCTCTG TGCTCACATG TGGGAGGGGG  
 343 K C K V S N K A L P A P I E K T I S K A K G Q P R E P Q V Y T L P P  
 2701 CATCCGGGA AGAGATGACC AAGGAGCC CGTGGCTGCAG TCAGGGAGG TCAGGGAGC TAGGGTCTGCTG GTAGGGCAGC CTGACCCCTCT CGTAAACCGT  
 GTAGGGCCCT TCTCTACTGG TTCTGGTC AGTCGAGCT GACGGAGCG TTTCCTAGA GACGGAGCG TTTCCTAGA GACGGAGCG TTTCCTAGA GACGGAGCG  
 377 S R E E M T K N Q V S L T C L V K G F Y P S D I A V E W E S N G Q  
 2801 GCGGAGACG AACTACAGA CCACGCCCTCC CGTGGCTGCAG TCCGACGGGT CCTTCAGCTCT CTACAGCAAG CTACACGGGG ACAGAGCAG GTGGCAGCAG  
 410 P E N N Y K T P P V L D S D G S F F L Y S K L T V D K S R W Q Q  
 2901 GGGAAAGCTCT TCTCATGTC CGTGATGATGAT GAGGGCTCTGC ACAACACATA CAGGAGAAG AGGCTCTCCC TGTCCTCGGG TAAATAAGGA TGAGCGCC  
 CCCTTGAGA AGGTGAGCA GCACTGAGTA CTCGAGACG TGTTGGTGTAT GTGGCTCTTC TGCGCTCTTC TGCGGAGGG ACAGAGCCC ATTATTCGT AGCGTGCCTG  
 443 G N V F S C S V M H Y T Q K S L S L S P G K O  
 3001 CTAGATGCC TAAGGGCTGG TTGGCTCTTA TTGTGAACTC ATGTTGACA GATAAGCTTC GATAAGCTTC GATAAGCTTC ATGCGGTAG TAAATGCTC  
 GATTCGAGG ATTCGAGSC AACGGGGGCC CGCAAAATAA ACAATGAG TAAATGAG TAAATGAG TAAATGAG TAAATGAG TAAATGAG TAAATGAG  
 3101 TAAATGCT AACGGAGCA GGCACCGGTG ATGAAATCTA ACAATGGCT CTCGGCTAC CTCGGCTAC CTCGGCTAC CTCGGCTAC CTCGGCTAC  
 ATTTAACGA TTGGCTCATG CCGTGGACAA TACTTGTAT TGTAGTGGAG GTCACGAGTAG AGTGGCTGG AGTGGCTGG AGTGGCTGG AGTGGCTGG  
 3201 TTAGGGCGT ACTGGGGGT CTCCTGGGG ATATGCTCCA TTTCGAGAGC ATCGGAGTC ACTATGGGT GCTGCTAGG CTATATGGT TGATGCAATT  
 AAATACGGCCA TGACGGCCCA GAGAACGCC GAGAACGCC TATAGCAGGT AAGGGCTCG TAGGGCTCG TAGGGCTCG GATATAGCA ACTACGGCA ACTACGGCA

Start Tet Resistance Coding Sequence

1 GAATTCAACT TCTCCATACT TTGGATAGG AAATACTGAC ATGAAAATC TCATTGCTGA GTTGTATT ATTAAAGAAGA AGAGTCGAAT  
CTTAAGTGA AGAGGTATGA AACTTATCC TTTATGTCG TACTTTAG AGTAACGACT CAACAAATAA TTGACGGG TTTCCTCTCT TCTCAGCTTA

101 GAACTGTGTC CGGAGGTAGA AGCTTGGG AGTATGCTCA CTGGATAGT TGGCAATATG GCGCAAAATG ACCRAAGGG GTTGATGAT CAGGTAGGG  
CTTGACACAC GCCTCCATCT TCGBAAACCTC TAATAGCTGT GACCTTGA AGGGTATAC CGCGTTTAC TGGTGTCTGC CAACTAATAA GTCCATCTCC

201 GGGCGCTGTA CGAGGTAAGG CCCGATGCCA GCATTCTGA CGACGATACG' GAGCTGGTC CGGATTAACG AAAGAAGTA TTGAGCCTC CTGCTGAGTA  
CCCGGACAT GCTCCATTC GGGCTACGGT CGTGAAGCT GCTGCTAATG CTCGACGAC CGCTPATGCA TTTCCTCAAT AACCTGPGAG GAGCACTCAT

301 AAAAGTTAAT CTTTCACA GCTGTCAAA AGTGTGTCG GCCGAGACTT ATAGTCGTT TTGTGTATT TTGTATGTA TTTCCTACTA GTAGCGAGT  
TTTTCATAA GAAAGTGT CGACAGTATT TCACAGTC CGGCTCTGA TATCAGGAA ACAAAATAA AAATACAT AAATATGAT CATGGTTCA

401 TCACGTTAAA AGGSTATCA GAAATGAA GAGAATTC GCAATTCTC TGGCATCTAT GTTGTGTTT TCTATGCTTA CAAAGCGTA CCTGATATC  
AGTGCATTIT TCCCATAGT CTTAATACCT CTCCTTATAG CGTAAAGAAG AACGTAGATA CAAGAAATAA AGTAAGAT GTTGTGCTA GGGACTATAG  
M K N I A F L L A S M F V F S I A T N A Y A D I  
^STII signal TIR -1 Anti-VEGF light chain

501 CAGTTCACCC AGTCCCCCG GCCTCTGTCG GCGATAGGT CACCATACC TCGAGGGCAA GTAGGATAAT TAGCAGTAT TAAACTGGT  
CTGCAACTGGG TCAGGGCTC GGGGACCC CGCTATCCA GTGTAGGG ACGTCTCGTT CAGTCCTATA ATCGTGTATA AATTGACCA  
26 Q L T Q S P S S L S A S V G D R V T I T C S A S Q D I S N Y L N W Y

601 ATCAACGAA ACCAGGAAAG GTCTCCACTC TCTCCTCCTA CTGCTCAACT CTGGAGTCCC TTCTGTTCTC TCTGGATCCG GTTCCTGGAC  
TAGTTGCTT TGGTCTCTT CGAGGCTTC ATGACTAATG AGATGAGGG AGAGGGAGG AGCTCTAGGG AAGGGAGG AGACCTAGGC CAAGACCTCG  
60 Q Q K P G K A P K V L I Y F T S S L H S G V P S R F S G S G T  
701 GGATTCACT CTGACCCATCA GGAGTCTCA GCCAGAGAC TTGCAAACTT ATTACTGCA ACAGTATAGC ACCTGGCTG AGAGGTGG AGAGGTGG  
CCTAAACTGA GACTGGTGT CGTCAGACTG CGGTAGACTA TAATGCACT TGTCTATCG TGGCACGGCA CCTGGCAAAAC TGTCCCATCG  
93 D F T L T I S S L Q P B D F A T Y Y C Q Q Y S T V P W T F G Q G T

801 AAGGTGGAA TCAAACGAAAC TGGGCTCA CCATGTGT TCTCTCTCC GCCATCTGTG GAGCAGTTGA AATCTGGAC TGTCTGTGTT GTGAGCTTC  
TTCACCTCT AGTCTGCT ACAGCGAGT GGTAGACAGA AGTAGAGGG CGGTAGACTA CTGGTACTT TTGACCTG AGGAAGCAA CACGGGAGC  
126 K V E I K R T V A A P S V F I F P P S D E Q L K S G T A S V V C L L

901 TGAATTAATCT CTATCCCGAA GAGGCCAAGAG TACAGTGAAG GGTGGTAC CCACCTATG CGGGAGTTA GCCCCTOCAT CGGGTAACCTC CCGGGAGAGT GTCACTAGAGC AGGAGAGAA  
ACTATGAA GATAGGGTTT CTGGGTTT ATGTCACCT CCACCTATG CGGGAGTTA GCCCCTOCAT CGGGAGTTA GCCCCTOCAT CGGGTAACCTC TCCGTCTCGT  
160 N N F Y P R E A K V Q W K V D N A L Q S G N S Q E S V T E Q D S K

1001 GGACGGCAC TACAGCCTCA GCAGCCCTT GAGGCAAGT AGGAGAAACA CAAGGTAC GCCTGGAG TCACCCATCA GGGCTGAGC  
CCTGTGTTGTT ATGTCGGGT CGTGTGGCA CTGGCTCTCG TTTCGTCTGA TGCTCTTGT GTTCTGAGT CGGAGCTTC AGTGGTGT CCGGACTCG  
193 D S T Y S L S S T L T S K A D X E K H K V Y A C E V T H Q G L S

1101 TCGCCGCTCA CAAGAGCTT CAACAGGGAA GAGTGTAAAT TAACTCTCT AGGCGGAGC CATGTGGGG AGCTGGTAC CCGGGGATCT AGGGCTAACG  
AGCGGGCACT GTTCTGAA GTTGTCCCT CTACAAATTA ATTAGGAA TGCGGGCTGC GTAGCACCC CGCCCTAGT GGCGCCATG TCGGATTG  
226 S P V T K S F N R G E C O

Figure 21a

1201 CTCGGTGGC GCCGGGGGTT TTTTATTGTT GCGGAGCCGC ATCTCGAATG AACTCTGGTC GCGAGGTAGAA GCTTGGGAGA TTATCGTCAC TGCATATGCTT  
 GAGGAAAGG CGGCCCGGAA AAAATAACAA CGGCCCGGAA AAAATAACAA CGGCCCGGAA AAAATAACAA CGGCCCGGAA AAAATAACAA CGGCCCGGAA  
 1301 CGCAATATG CCAACAGCG AGGTGATC AGGTGATC AGGTGATC AGGTGATC AGGTGATC AGGTGATC AGGTGATC AGGTGATC AGGTGATC  
 GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT  
 1401 AGCTCGGG CGATTAGTA AGAGATATG TGAAGCTTC TCGTCAGTA AAAGTAAATC TTTCATTAG AAAGTAAATC TTTCATTAG AAAGTAAATC  
 TCGAGGACGC GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG  
 1501 TAGTCGCTT GTTTTATT TTTATGAT TTGTTACTAG TAGCGAAGTT CACGTAAGAA GGTATCTAG AATTATGAG AAGATATG CATTTCTCT  
 ATCAGGAAAA CAAAATAAA AAATACATA AACATGATC ATGCGTAC GCGTATACCG CGCTTACT GCGTATACCG CGCTTACT GCGTATACCG  
 1 \*STII signal TIR-1

1601 TGCATCTATG TCGTTTTT CTATGCTAC AAAGGGTAC GCTGGGGTAC AGCTGGTTC AGCTGGTTC GCTGGGGTAC AGCTGGGGTAC  
 AGCTGGGGTAC AGCTGGGGTAC GATAAGGATG TTGGGGATG CGACTCAG CGACTCAG CGACTCAG CGACTCAG CGACTCAG CGACTCAG  
 10 A S M P V F S I A T N A Y A E V Q L V E S G G L V Q P G G S L R  
 \*Anti-VEGF Heavy Chain

1701 TTGTCCTGTG CAGCTCTGG CTACGACTTC ACCGACTACAG GTCATGACTG GTCATGACTG CTCATGACTG CTCATGACTG  
 AACAGGAAAC GTCGAAGGCC GATGCTGAG TGCTGCTGAG CTCATGACTG CTCATGACTG CTCATGACTG CTCATGACTG  
 43 L S C A A S G Y D F T H Y G M N W V R Q A P G K G L E W V G W I N T  
 77 Y T G E P T Y A A D F K R R F T P S L D T S . K T A Y L Q M N S L

1801 CCTATACGG TGAACGACCC TATGCTCGG ATTCAAAAGC TGTTTACT TTTCCTTGTG ACACCTCCAA AACGACCCAA AACGACCCAA  
 GCGATATGCC ACTTGCGCG ATACGAGGCC TAATGTTGC ACCAAAGTGA AAAGAAATC TGTTGAGGT TTGTGAGGT ATGAGGTCT ACTTGCGCG  
 110 R A E D T A V Y Y C A K Y P Y Y G T S H W Y F D V W G Q G T L V

1901 GCGCGCTAG GACACTGGC TCTATATCT TGCAAGGTAC CGCTACTATT AGCGACGAG CGACTGGTAT TTGACGCTCT GGGTCAGG AACCCGTGCT  
 CGCGGACTC CTGTCAGGC AGATATGAC AGGTTCATG GCGATGATAA TGCGGTGTC GETGATGATAA AGGTTCATG GCGATGCTC TTGGACCG  
 2001 ACGGCTCTCT CGGCCCTCAC CAGGGGCCA TCGGCTCTCC CCTCTCCAG ACCACCTCTG GGGCCCTGGC GGGCCCTGGC TGCCCTGGCA  
 TGGAGAGGA GCGGAGGTG GCGGAGGTG AGCCAGAAGG GGGACCTGG AGCCAGAAGG GGGACCTGG AGCCAGAAGG GGGACCTGG  
 143 T V S S A S T K G P S V F P L A P S S K S T S G G T A A L G C L V K  
 177 D Y F P E P V T V S W N S G A L T S G V H T F P A V L Q S S G L Y

2101 AGGACTACTT CCCCGAACCG GTGACGGTGT CGTGGAACTC AGGGGGCTGT ACCACGGGG TGACACCTT CCCGGCTCTC CTACAGCTCT  
 TCCCTGATAA GGGGTTGGC CACTGCAACG GCACCTGTG TGCGGGGAC TGCGGGGAC ACCCTGAGA GGGGGAGC GATGAGGA GTCTGAGAT  
 2201 CTCCCTGAGC AGGCTGGTGA CTGTCCTCTG TAGCACCTG GGCACCCAGA CCTAACATCTG CACGTGAAT CACAGGCCA GCAACACAA GTGACGACAG  
 GAGGGAGCTG TGCGCAACT GACAGGGGG ATCTGGAAC CGCTGGGCTCT GGATCTGAGC GTGCACTTA GTGTCGGGT CTGTCGGGT  
 210 S L S S V V T V P S S L G T Q T Y I C N V N H K P S N T K V D K  
 2301 AAAGTTGAGC CCACATCTG TGACAAACT CACACATGCC ACCCTGAA CTCCTGGGG GACCGTCAGT CTTCCTCTC CCCCTAACAC  
 TTTCRACCTG GGTGAAAC ACTGTTGAGC ATCTGGAAC CGCTGGGCTCTG GTGTCGGGT CTGTCGGGT CTGTCGGGT  
 243 K V E P K S C D K T H T C P P C P A P E L L G G P S V F L F P P K P  
 2401 CCAAGGACAC CCTCATGATC TCCGGACCC CTGAGGTCAC ATGGCTGGTG GTGGAGCTGA GCCACGAGAA CCTGAGGTC ACCTGAACT  
 GGTTCCTGAGG GGGGTTGGC GACCTGAGTAC AGGGCTGGG GACCTGAGTAC AGGGCTGGG GACCTGAGTAC AGGGCTGGG  
 277 K D T L M I S R T P E V T C V V V D V S H E D P E V K F N W Y V D

2501 CGGGGTGGAG GTGCGATAATG CCAAGAGCAA GCCCGGGGGAG GAGGAGCTAA ACAGGAGCTAA CGGTGCTGGTC AGCGTCCTCA CGGTCTGCA CGAGGACTGG  
 GCCGCACCTC CACGPTTAC GGTTCCTTC CTCGTCATGT TGTCGTCATGT TGTCGTCATGT GGCACAGCAG TCGAGAGGT GGCAAGACGT GGTCTGACCC  
 310 G V E V H N A K T K P R E E Q Y N S T Y R V V S V L T V L H Q D W  
 2601 CTGATGGCA AGGAGTACAA GTGCAAGGT TCCAAACAAAG CCCATCGAG AAACCATCT CCAAGCCAA AGGGAGGCCA CGAGGACCC  
 GACTAACGT TCCATGTT CACGTCAG AGGTGTTTC GGAGGGTCTC TTGGTAGCTC TTGGTAGCTC TTGGTAGCTC TTGGTAGCTC TTGGTAGCTC  
 343 L N G K E Y K C K V S N K A L P A P I E K T I S K A K G Q P R E P Q  
 2701 AGGTGTCAC CCGTGGCCCA TCCGGGGAG AGATGACCA GAACTGGAG AGCCGTGACCT GCGTGGCTAA AGGCTCTAT CCCAGGACCA TCGCCGTGGA  
 TCCACATGTC GAACTGGGGT AGGGCCCTTC TCTACGTTT CTTGGTCAG TGGAAGGA CGGACAGTT TCCGAGATA GGTCGCTGT AGGGACCT  
 377 V Y T L P P S R E E M T K N Q V S L T C L V K G F Y P S D I A V E  
 2801 GTGGGAGGC ATGGGGAGC CGGAGAACAA CTAAAGAGC AGCGCTCCCGC TGCTGGACCT CGAGGGCTCC TTCTTCCTCT ACAGCAAGT CACCGTGAC  
 GCTCTCTCG TTACCCCTCG GCCTCTCTCG TTATGTTG TGCGAGGSC AGGACCTGAG GCTGCGAGGSC ARGAGAGA TGTCGCTCA GNGGACCTG  
 410 W E S N G Q P E N N Y K T T P P V L D S D G S F F L Y S K L T V D  
 2901 AAGAGGAGGT GGCAAGGGG GAAAGCTCTC TCTATGCTCG TGATGCTCG AACCACTACA CGCAGGAGAG CCTCTCCCTG GGAGGGGAC AGAGGCCAT  
 TTCTGCTCA CGCTCGTCC CTTGCAAGAG ATGAGGGC ACTAGTGAATC CGAGGAGCTG TTGGTGAATG GCCTCTCTC TTCTGCTCA GNGGACCTG  
 443 K S R W Q Q G N V P S C S V M H E A L H N H Y T Q K S L S P G K  
 3001 ATTAAGGATG CGAGGGCCCT AGAGTCCTA AGCGTCGGTT GCCGGGGGC GTTTTATT GTTAATCTAT GTTGACAGC TTATCATGA TAAGCTTAA  
 TTATTCGTCAC GCTGGGGAA TCTCAGGGAT TGCGAGCTAA CGGGGGCCCG CAAAAATPA CRAATTGAGTA CAAACTGTG AATATGAGCT ATTGAATT  
 477 O  
 3101 TGGGGTAGT TATCACAGT AAATGGTAA CGCAGTCAGG CACCGTGTAT GAATCTAC ATGGCTCA TCGTCATCT CGGCACCGTC ACCCTGGTC  
 ACCCCATCA ATATGTCATCA TTTAACATT GGTGCTGTC GTGGACATA CTTCAGTGTG TTAAGGAGT AGCAATAGGA GCGTGGCAG GGGACCTAC  
 Start re Resistance Coding Sequence  
 3201 CTGTAGGAT AGGTGTTT ATGCCGGTAC TGCGGGGCTT CTGGCGGGAT ATCGTCATT CGCACAGCAT CGGAGTCAC TATGGCTGTC TGCTAGGCT  
 GACATCCGTA TCCGACCAA TACGGCGAT AGGGCCCTG AGGGCCGGAA GAACTGGTA GGTCGCTGA ATACCGCAGC AGCATCGCA




Figure 22

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number  
WO 02/061090 A3(51) International Patent Classification<sup>7</sup>: C12N 15/13,  
15/70, 1/21, C07K 16/00, 19/00, A61K 47/48

C. [US/US]; 1313 Grove Avenue, Burlingame, CA 94010 (US). KLIMOWSKI, Laura [CA/US]; 474 East 2nd Avenue, Salt Lake City, UT 84103 (US). REILLY, Dorothea E. [US/US]; 334 Mount Vernon, San Francisco, CA 94112-3634 (US). YANSURA, Daniel G. [US/US]; 330 Carmel Avenue, Pacifica, CA 94044 (US).

(21) International Application Number: PCT/US01/48691

(74) Agent: CUI, Steven X.; c/o GENENTECH, INC., MS 49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(22) International Filing Date:  
13 December 2001 (13.12.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

(26) Publication Language: English


(30) Priority Data:  
60/256,164 14 December 2000 (14.12.2000) US

[Continued on next page]

(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, SOUTH SAN FRANCISCO, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SIMMONS, Laura



WO 02/061090 A3

(57) Abstract: The present invention provides methods and compositions for improved expression and production of recombinant antibodies in prokaryotic expression systems. Particularly contemplated are prokaryotic expression and production of full-length glycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.



European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report: 21 August 2003

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## INTERNATIONAL SEARCH REPORT

International Application No

PC., JS 01/48691

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/13 C12N15/70 C12N1/21 C07K16/00 C07K19/00  
A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE, SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 19196 A (BOLT SARAH LOUISE ;CLARK MICHAEL RONALD (GB); GORMAN SCOTT DAVID () 30 September 1993 (1993-09-30) claim 1	28-41
X	BOYD P N ET AL: "THE EFFECT OF THE REMOVAL OF SIALIC ACID, GALACTOSE AND TOTAL CARBOHYDRATE ON THE FUNCTIONAL ACTIVITY OF CAMPATH-1H" MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 32, no. 17/18, 1995, pages 1311-1318, XP000676340 ISSN: 0161-5890 the whole document	28-41

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search	Date of mailing of the International search report
21 May 2003	06/06/2003
Name and mailing address of the ISA	Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Wagner, R

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/48691

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANDREAS SCHMIEDL AND STEFAN DÜBEL: "Antibody Engineering" 2001, SPRINGER, BERLIN HEIDELBERG XP002241889 page 257 ---	1-41
A	WO 93 08300 A (UNIV CALGARY; NG SHI CHUNG (CA); ANTHONY JAMES G (CA); WONG SUI LA) 29 April 1993 (1993-04-29) the whole document ---	1-27
A	US 5 747 662 A (SIMMONS LAURA C ET AL) 5 May 1998 (1998-05-05) the whole document ---	1-27
A	EP 0 731 167 A (XOMA CORP) 11 September 1996 (1996-09-11) example 7 ---	1-27
T	SIMMONS LAURA C ET AL: "Expression of full-length immunoglobulins in Escherichia coli: Rapid and efficient production of aglycosylated antibodies." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 263, no. 1-2, 2002, pages 133-147, XP002241888 1 May, 2002 ISSN: 0022-1759 the whole document ---	1-41

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/48691

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9319196	A 30-09-1993	AT	155818 T	15-08-1997
		AU	671085 B2	15-08-1996
		AU	2766892 A	21-10-1993
		DE	69221147 D1	04-09-1997
		DE	69221147 T2	15-01-1998
		EP	0586617 A1	16-03-1994
		ES	2106195 T3	01-11-1997
		WO	9319196 A1	30-09-1993
		GR	3024489 T3	28-11-1997
		JP	7500017 T	05-01-1995
		KR	238497 B1	15-01-2000
		US	5585097 A	17-12-1996
WO 9308300	A 29-04-1993	WO	9308300 A1	29-04-1993
US 5747662	A 05-05-1998	NONE		
EP 0731167	A 11-09-1996	EP	0731167 A1	11-09-1996
		AT	102249 T	15-03-1994
		EP	0550400 A2	07-07-1993
		AT	140266 T	15-07-1996
		AT	197315 T	15-11-2000
		AU	632462 B2	07-01-1993
		AU	2324488 A	01-03-1989
		CA	1341235 C	22-05-2001
		DE	3855421 D1	14-08-1996
		DE	3855421 T2	06-03-1997
		DE	3856440 D1	07-12-2000
		DE	3856440 T2	13-06-2001
		DE	3888186 D1	07-04-1994
		DE	3888186 T2	22-09-1994
		DK	19290 A	23-03-1990
		EP	0371998 A1	13-06-1990
		JP	2991720 B2	20-12-1999
		JP	3501321 T	28-03-1991
		WO	8900999 A1	09-02-1989
		US	5618920 A	08-04-1997
		US	5595898 A	21-01-1997
		US	5576195 A	19-11-1996
		US	5693493 A	02-12-1997
		US	5698417 A	16-12-1997
		US	5698435 A	16-12-1997
		US	6204023 B1	20-03-2001
		US	5846818 A	08-12-1998